Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
PFE Stock News and Mentions of Pfizer Inc. Stocktwits
Updated: April 28, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Pfizer Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Pfizer Inc. (PFE).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Pfizer stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Pfizer Inc. (PFE)
April 28, 2024 (11:30) / "CNN" (by Nicole Goodkind)
What is divestment? And does it work? | Business
What is divestment? And does it work? CNN International ...
In Article Trend: Neutral
April 28, 2024 (11:30) / "CNN" (by Nicole Goodkind)
What is divestment? And does it work? | Business
What is divestment? And does it work? ...
In Article Trend: Neutral
April 28, 2024 (09:50) / "Motley Fool" (by Keith Speights)
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
In Article Trend: Somewhat-Bullish
April 27, 2024 (11:15) / "Motley Fool" (by Keith Speights)
3 Dividend Stocks to Buy and Hold for the Next Decade
You'll get dividends and more with these great stocks.
In Article Trend: Somewhat-Bullish
April 27, 2024 (02:33) / "Benzinga" (by Ananya Gairola)
Jim Cramer Weighs In Ahead Of Apple, Amazon, Eli Lilly Earnings: 'We Have To Run Such A Ridiculous Gauntlet Next Week' - Apple ( NASDAQ:AAPL ) , Amazon.com ( NASDAQ:AMZN )
Jim Cramer, the host of CNBC's "Mad Money," has outlined the key events that investors should keep an eye on in the upcoming week. What Happened: Cramer highlighted the significant events scheduled for the week, including earnings reports from Apple Inc. AAPL, Amazon.com Inc.
In Article Trend: Neutral
April 26, 2024 (22:28) / "CNBC" (by Julie Coleman)
Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly
CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.
In Article Trend: Neutral
April 26, 2024 (22:17) / "Investors Business Daily" (by ALAN R. ELLIOTT)
Apple, Amazon, Big Pharma And The Fed: Investing Action Plan
A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 26, 2024 (18:45) / "Benzinga" (by Vandana Singh)
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle - CureVac ( NASDAQ:CVAC )
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV CVAC have settled Acuitas' lawsuit over credit for inventions tied to COVID-19 vaccines. In November 2023, Acuitas Therapeutics filed a lawsuit in Virginia federal court against CureVac, accusing it of failing to credit ...
In Article Trend: Neutral
April 26, 2024 (18:30) / "Benzinga" (by Vandana Singh)
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia - Pfizer ( NYSE:PFE )
Friday, the FDA approved Pfizer Inc's PFE Beqvez ( fidanacogene elaparvovec-dzkt ) for moderate to severe hemophilia B in adult patients who currently use factor IX ( FIX ) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous ...
In Article Trend: Neutral
April 26, 2024 (15:34) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
In Article Trend: Somewhat-Bullish
April 26, 2024 (14:02) / "Benzinga" (by Benzinga Insights)
Pfizer's Options: A Look at What the Big Money is Thinking - Pfizer ( NYSE:PFE )
Deep-pocketed investors have adopted a bullish approach towards Pfizer PFE, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Neutral
April 26, 2024 (13:15) / "Zacks Commentary" (by Zacks Equity Research)
Gear Up for Pfizer ( PFE ) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
In Article Trend: Somewhat-Bullish
April 26, 2024 (12:45) / "Zacks Commentary" (by Zacks Equity Research)
AbbVie ( ABBV ) Beats Q1 Earnings and Revenue Estimates
AbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Somewhat-Bullish
April 26, 2024 (12:30) / "GlobeNewswire" (by Biodexa Pharmaceuticals PLC)
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis ( FAP )
April ...
In Article Trend: Neutral
April 26, 2024 (11:45) / "Motley Fool" (by David Jagielski)
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
Put your money to work by investing in these three high-quality dividend stocks.
In Article Trend: Somewhat-Bullish
April 26, 2024 (11:02) / "CNBC" (by Annika Kim Constantino)
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
In Article Trend: Neutral
April 26, 2024 (10:46) / "Investors Business Daily" (by Investor's Business Daily)
Pfizer Now Rivals The World's Most Expensive Medicine
Pfizer Stock: Pharma Giant Takes On Hemgenix, The World's Most Expensive Drug Investor's Business Daily ...
In Article Trend: Neutral
April 26, 2024 (08:50) / "Motley Fool" (by Adria Cimino)
Should You Buy Moderna Before May 12?
This ambitious biotech aims to launch 15 products over the coming five years.
In Article Trend: Somewhat-Bullish
April 26, 2024 (02:16) / "Benzinga" (by Zacks)
Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat - ADMA Biologics ( NASDAQ:ADMA ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
Bristol-Myers Squibb Company BMY reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the year-ago quarter, BMY posted adjusted earnings per share of $2.05.
In Article Trend: Neutral
April 25, 2024 (20:45) / "PR Newswire" (by Inc.)
Mahesh Krishnan Elected to Halozyme's Board of Directors
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. ( NASDAQ: HALO ) ( "Halozyme" ) today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
In Article Trend: Somewhat-Bullish
April 25, 2024 (20:05) / "Benzinga" (by Globe Newswire)
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study - Aligos Therapeutics ( NASDAQ:ALGS )
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting SOUTH SAN FRANCISCO, Calif., April 25, 2024 ( GLOBE NEWSWIRE ) -- Aligos Therapeutics, Inc.
In Article Trend: Somewhat-Bullish
April 25, 2024 (18:27) / "PR Newswire" (by BioNJ)
BioNJ Announces Lineup for BioPartnering Conference
TRENTON, N.J., April 25, 2024 /PRNewswire/ -- BioNJ is pleased to host its 14th Annual BioPartnering Conference on Tuesday, May 14, at the Liberty Science Center in Jersey City. Sponsored by J.P.
In Article Trend: Bullish
April 25, 2024 (17:51) / "Benzinga" (by Vandana Singh)
What's Going On With Pfizer Stock On Thursday? - GSK ( NYSE:GSK ) , Pfizer ( NYSE:PFE )
GSK Plc GSK has reportedly taken legal action against Pfizer Inc PFE and BioNTech SE BNTX in a Delaware federal court, alleging patent infringement concerning mRNA technology used in the COVID-19 vaccines. The lawsuit contends that Pfizer and BioNTech's Comirnaty vaccines violate GSK's patents.
In Article Trend: Neutral
April 25, 2024 (15:48) / "Zacks Commentary" (by Zacks Equity Research)
Bristol-Myers ( BMY ) Q1 Loss Narrower Than Expected, Sales Beat
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
In Article Trend: Neutral
)
April 25, 2024 (15:18) / "Business Standard" (by Reuters)
GlaxoSmithKline sues Pfizer, BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA ( mRNA ) technology in the companies' blockbuster COVID-19 vaccines.
In Article Trend: Somewhat-Bearish
April 25, 2024 (13:15) / "PR Newswire"
Rutgers Dual Degree program enabled graduate student to pursue interest in healthcare while she earned an MBA - PR Newswire
Rutgers Dual Degree program enabled graduate student to pursue interest in healthcare while she earned an MBA PR ...
In Article Trend: Bullish
April 25, 2024 (12:30) / "Investors Business Daily" (by ALLISON GATLIN)
How Big Pharma Is Taking A Page Out Of Novartis' Playbook
Biotech Stocks: Big Pharma Eyes $25 Billion Radiopharmaceuticals Market Investor's Business Daily ...
In Article Trend: Neutral
April 25, 2024 (11:35) / "CNBC" (by Annika Kim Constantino)
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
In Article Trend: Neutral
April 25, 2024 (10:32) / "CNBC" (by Annika Kim Constantino)
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.
In Article Trend: Neutral
April 24, 2024 (16:05) / "Zacks Commentary" (by Sweta Killa)
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
In Article Trend: Neutral
April 24, 2024 (15:00) / "Canada Newswire" (by Pfizer Canada Inc.)
VELSIPITY™ Receives Health Canada Approval for Adults with Moderately to Severely Active Ulcerative Colitis ( UC )
VELSIPITY is a once-daily, oral, sphingosine 1-phosphate ( S1P ) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5.
In Article Trend: Neutral
April 24, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Analysts Estimate Pfizer ( PFE ) to Report a Decline in Earnings: What to Look Out for
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 23, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Corneal Implant Market is Expected to Showcase a Significant Growth at a CAGR of ~6% by 2030 | DelveInsight
The surge in demand for corneal implants stems mainly from the rise in instances of corneal blindness, eye injuries, and conditions like ocular hypertension ( glaucoma ) .
In Article Trend: Somewhat-Bullish
April 23, 2024 (19:00) / "Benzinga" (by Vandana Singh)
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown - Moderna ( NASDAQ:MRNA ) , Pfizer ( NYSE:PFE ) , BioNTech ( NASDAQ:BNTX )
Moderna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London patent trial concerning the development of COVID-19 vaccines. The High Court is slated to address a legal complaint brought by Moderna.
In Article Trend: Neutral
April 23, 2024 (13:20) / "Investors Business Daily" (by Investor's Business Daily)
The No. 1 Biotech Stock Just Launched Higher - Here's Why
Biotech Stock Neurocrine Launches Higher On A Depression Treatment Win Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 23, 2024 (13:15) / "Motley Fool" (by George Budwell)
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment?
In Article Trend: Somewhat-Bullish
April 23, 2024 (12:15) / "Motley Fool" (by George Budwell)
1 No-Brainer Vanguard Fund to Buy Right Now
This Vanguard growth fund is home to some of the world's most innovative companies.
In Article Trend: Somewhat-Bullish
April 23, 2024 (12:01) / "Canada Newswire"
Pfizer Canada and McMaster University to foster health equity in vaccine science - Canada NewsWire
Pfizer Canada and McMaster University to foster health equity in vaccine science Canada ...
In Article Trend: Bullish
April 22, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Rises Higher Than Market: Key Facts
Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.
In Article Trend: Neutral
April 22, 2024 (15:31) / "Benzinga" (by Benzinga Insights)
Pfizer Options Trading: A Deep Dive into Market Sentiment - Pfizer ( NYSE:PFE )
Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer PFE revealed 18 unusual trades. Delving into the details, we found 66% of traders were bullish, while 27% showed bearish tendencies.
In Article Trend: Neutral
April 22, 2024 (10:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
MAINZ, Germany, April 22, 2024 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT ( 2:00 ...
In Article Trend: Neutral
April 21, 2024 (06:14) / "Stocknews.com" (by Defense World Staff)
Pieris Pharmaceuticals ( NASDAQ:PIRS ) Earns Hold Rating from Analysts at StockNews.com
Equities research analysts at StockNews.com started coverage on shares of Pieris Pharmaceuticals ( NASDAQ:PIRS - Get Free Report ) in a report released on Sunday. The firm set a "hold" rating on the biotechnology company's stock. Shares of PIRS stock opened at $0.15 on Friday.
In Article Trend: Somewhat-Bullish
April 20, 2024 (09:50) / "Motley Fool" (by Keith Speights)
3 Stocks Under $50 You Can Buy Hand Over Fist Right Now
A little up-front investment can go a long way with these three stocks.
In Article Trend: Somewhat-Bullish
April 19, 2024 (16:07) / "Barrons" (by Andy Serwer)
CEO Compensation Rose to Another Record in 2023
CEO Pay Rose to Another Record in ...
In Article Trend: Neutral
April 19, 2024 (16:07) / "Barrons" (by Andy Serwer)
CEO Compensation Rose to Another Record in 2023
CEO Pay Rose to Another Record in ...
In Article Trend: Somewhat-Bullish
April 19, 2024 (14:08) / "Forbes" (by John Navin)
Pfizer On The New Lows List. Big Dividend Fails To Attract Buyers.
That Pfizer is making the new 52-weeks lows list is not a proud moment for the company. You might think that a big, well-known healthcare firm offering a 6.6% dividend would attract investors. So far, this year that hasn't been the case as the stock just keeps dropping despite the nice yield and ...
In Article Trend: Neutral
April 19, 2024 (13:15) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
In Article Trend: Neutral
April 19, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Here is What to Know Beyond Why Pfizer Inc. ( PFE ) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
April 19, 2024 (12:00) / "GlobeNewswire" (by Biodexa Pharmaceuticals PLC)
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 18, 2024 (19:44) / "PR Newswire" (by ProSource360)
ProSource360 wins opportunity to partner with Pfizer through its Diverse OnDemand Marketplace
Firm becomes one of only 11 selected to supply professional services through unique model! WASHINGTON, April 18, 2024 /PRNewswire/ -- ProSource360 announces it has been chosen to participate in Pfizer's Diverse OnDemand pilot program, a procurement-developed self-serve tool designed to simplify ...
In Article Trend: Bullish
April 18, 2024 (19:44) / "Benzinga" (by PRNewswire)
ProSource360 wins opportunity to partner with Pfizer through its Diverse OnDemand Marketplace
WASHINGTON, April 18, 2024 /PRNewswire/ -- ProSource360 announces it has been chosen to participate in Pfizer's Diverse OnDemand pilot program, a procurement-developed self-serve tool designed to simplify the diverse supplier contracting process.
In Article Trend: Bullish
April 18, 2024 (13:15) / "Motley Fool" (by Selena Maranjian)
If You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today
The answer to that question will either make you wince or smile.
In Article Trend: Somewhat-Bullish
April 18, 2024 (12:00) / "Motley Fool" (by Jeremy Bowman)
Think Amazon Is Done Growing? 3 Reasons It Could Reach $1 Trillion in Revenue.
Management's annual shareholder letter detailed Amazon's expected path to growth.
In Article Trend: Somewhat-Bullish
April 18, 2024 (11:26) / "Motley Fool" (by Selena Maranjian)
Years' Worth of Passive Income Is Hiding in Plain Sight
There are many ways to create lasting income streams that will continue to deliver cash year after year with little effort from you. It's a beautiful thing.
In Article Trend: Bullish
April 17, 2024 (22:51) / "Business Insider" (by Yiannis Zourmpanos)
The 3 Most Overlooked Stocks Set for a Triple-Digit Comeback
Hidden treasures sometimes go overlooked in the busy world of financial markets. Here, attention is frequently drawn to the names with the most sparkle. The purpose of this piece is to highlight three of these less shiny treasures. The first one sticks out for its unwavering dedication to ...
In Article Trend: Somewhat-Bullish
April 17, 2024 (11:00) / "PR Newswire" (by Canaan)
Canaan Adds Accomplished Executive and Scientist, Uwe Schoenbeck, Ph.D., Along with New Capital, to Bolster its Biopharma Investment Efforts
Canaan Adds Accomplished Executive and Scientist, Uwe Schoenbeck, Ph.D., Along with New Capital, to Bolster its ... PR ...
In Article Trend: Somewhat-Bullish
April 17, 2024 (10:30) / "Forbes" (by Alexandra S. Levine)
TikTok Mishandled The Data Of Hundreds Of Top American Advertisers
Sensitive business information from advertisers like Amazon, Disney and the New York Times was widely available to ByteDance staff across the U.S. and China, Forbes has learned. TikTok, which is fighting a ban over its handling of data, declined to comment.
In Article Trend: Neutral
April 17, 2024 (09:21) / "Motley Fool" (by Sean Williams)
3 No-Brainer Stocks to Buy With $100 Right Now
A modest amount of money can go a long way in the stock market when it's put to work in time-tested businesses with well-defined competitive advantages.
In Article Trend: Somewhat-Bullish
April 16, 2024 (15:49) / "Benzinga" (by Upwallstreet)
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff - Johnson & Johnson ( NYSE:JNJ )
On Tuesday, Johnson & Johnson JNJ delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates.
In Article Trend: Neutral
April 15, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Why the Market Dipped But Pfizer ( PFE ) Gained Today
Pfizer (PFE) closed the most recent trading day at $25.91, moving +0.19% from the previous trading session.
In Article Trend: Neutral
April 15, 2024 (13:46) / "Benzinga" (by Benzinga Insights)
A Closer Look at Pfizer's Options Market Dynamics - Pfizer ( NYSE:PFE )
Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer PFE revealed 11 unusual trades. Delving into the details, we found 9% of traders were bullish, while 90% showed bearish tendencies.
In Article Trend: Neutral
April 15, 2024 (13:00) / "Motley Fool" (by George Budwell)
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:45) / "Motley Fool" (by Alex Carchidi)
Is Pfizer Stock a Buy?
The pharmaceutical giant is laying the groundwork for its next heyday.
In Article Trend: Somewhat-Bullish
April 15, 2024 (10:15) / "Forbes" (by Seth Matlins)
The 2024 Forbes Entrepreneurial CMO 50
The entrepreneurial approach to driving business growth and strategic advantage that these marketing leaders take is beholden to neither the status quo nor disrupting it for disruption's sake. ot every good-or even every great-CMO is also an entrepreneurial one.
In Article Trend: Somewhat-Bullish
April 15, 2024 (10:00) / "Benzinga" (by Globe Newswire)
Shah Capital nominates two highly qualified independent director candidates for Novavax - Novavax ( NASDAQ:NVAX )
RALEIGH, N.C., April 15, 2024 ( GLOBE NEWSWIRE ) -- Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax NVAX, has today issued the below statement:
In Article Trend: Somewhat-Bullish
April 15, 2024 (08:53) / "Motley Fool" (by Cory Renauer)
Want $1,000 in Annual Dividend Income? Invest $13,200 in These Ultra-High-Yield Dividend Stocks.
The average yield from these stocks is more than five times the market average.
In Article Trend: Somewhat-Bullish
)
April 15, 2024 (05:20) / "Business Standard" (by Reuters)
US-based Hedge fund Shah Capital urges Novavax board shake-up: Report
US-based hedge fund Shah Capital wrote to the Novavax board on Monday to push for the instalment of two new independent directors, the Financial Times reported on Monday.
In Article Trend: Somewhat-Bearish
April 14, 2024 (10:18) / "Forbes" (by Katherine Hignett)
England Launches Latest Round Of Covid-19 Booster Vaccines
England has launched its latest Covid-19 booster campaign for those at the highest risk from the disease. From Monday, people over the age of 75, those who live in adult care homes and others with certain underlying health conditions will be able to book a free shot to boost their protection ...
In Article Trend: Neutral
April 14, 2024 (07:00) / "Barrons" (by Ed Lin)
Large Fund Bets Big on Groceries in the Face of Persistent Inflation
Large Fund Bets Big on Groceries Through Walmart, Kroger Stock ...
In Article Trend: Somewhat-Bullish
April 14, 2024 (01:44) / "Barrons" (by Julie JAMMOT)
Race For AI Isn't Zero-sum, Says Amazon Cloud Boss
As Google races with Microsoft and OpenAI to create world-changing generative artificial intelligence, some critics see Amazon as lagging behind. "I respectfully disagree" with that viewpoint, said Adam Selipsky, Amazon's cloud chief, in an interview with AFP.
In Article Trend: Somewhat-Bullish
April 13, 2024 (09:47) / "Motley Fool" (by Keith Speights)
The Smartest Dividend Stocks to Buy With $400 Right Now
These three stocks are bargains with great dividends.
In Article Trend: Somewhat-Bullish
April 13, 2024 (05:09) / "Canada Newswire"
All International Medical Approval News and Press Releases from Cision Canada
VANCOUVER, BC, April 5, 2024 /CNW/ - Asep Medical Holdings Inc. ( "Asep" or the "Company" ) ( CSE: ASEP ) ( OTCQB: SEPSF ) ( FSE: JJ8 ) is very pleased to... MONTREAL, March 25, 2024 /CNW/ - Innodem Neurosciences, a leading digital health and AI company, announced today that its ...
In Article Trend: Somewhat-Bullish
April 13, 2024 (02:28) / "Business Insider" (by Plentisoft)
QFunction: Cybersecurity Company Announces Launch of Customized AI Solutions
Torrance, CA - QFunction is excited to announce the launch of its tailored cybersecurity solutions that help medium to large sized businesses and CISOs protect their data, assets, and reputation from cyber threats and attacks by leveraging the power of AI. Created by cybersecurity, threat ...
In Article Trend: Somewhat-Bullish
April 12, 2024 (23:46) / "Business Insider" (by markets.businessinsider.com)
QFunction: Cybersecurity Company Announces Launch of Customized AI Solutions
QFunction is excited to announce the launch of its tailored cybersecurity solutions that help medium to large sized businesses and CISOs protect their data, assets, and reputation from cyber threats and attacks by leveraging the power of AI.
In Article Trend: Somewhat-Bullish
April 12, 2024 (22:30) / "Barrons"
Big Pharma: Investment Bedrock
This is an outstanding article with big implications ( "Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake," Cover Story, April 4 ) . These companies are largely responsible for both extending life and quality of life, and are then demeaned by the political demagogues as ...
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:22) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
In Article Trend: Neutral
April 12, 2024 (13:00) / "Benzinga" (by Globe Newswire)
QFunction: Cybersecurity Company Announces Launch of Customized AI Solutions
QFunction is excited to announce the launch of its tailored cybersecurity solutions that help medium to large sized businesses and CISOs protect their data, assets, and reputation from cyber threats and attacks by leveraging the power of AI.
In Article Trend: Somewhat-Bullish
April 12, 2024 (12:14) / "Forbes" (by Danielle Chemtob)
Daily: New DOJ Rules Aim To Close 'Gun Show Loophole'
This is a published version of the Forbes Daily newsletter, you can sign-up to get Forbes Daily in your inbox here. Like many organizations these days, the Oakland International Airport wants a rebrand.
In Article Trend: Neutral
April 12, 2024 (10:35) / "Motley Fool" (by David Jagielski)
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
Is there still too much risk surrounding this business?
In Article Trend: Neutral
April 12, 2024 (10:30) / "Forbes" (by Giacomo Tognini)
Meet The Billionaire-Owned Company Making Injectors For Blockbuster Drugs Like Ozempic
Billionaire-Owned SHL Medical Makes Injectors For Drugs Like Ozempic Forbes ...
In Article Trend: Neutral
April 12, 2024 (10:07) / "Motley Fool" (by Cory Renauer)
2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever
These dividend payers have a long history of steady dividend payout raises, and they both offer yields above 6% at recent prices.
In Article Trend: Neutral
April 12, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Is Pfizer Stock the Biggest Bargain in the S&P 500?
When something seems too good to be true it might not be.
In Article Trend: Neutral
April 11, 2024 (20:21) / "Forbes" (by Ty Roush)
CDC Finds No Link Between COVID Vaccines And Cardiac Death In Young People
There is no evidence to suggest COVID vaccines could cause sudden cardiac death and other heart problems in young people, the Centers for Disease Control and Prevention said Thursday, following a string of unfounded conspiracy theories in recent years linking the vaccines to cardiac arrest in ...
In Article Trend: Somewhat-Bearish
April 11, 2024 (13:12) / "Zacks Commentary" (by Zacks Equity Research)
Will Pfizer's ( PFE ) New Drugs Provide a Boost to 2024 Sales?
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
In Article Trend: Somewhat-Bullish
April 11, 2024 (13:12) / "Zacks Commentary" (by Zacks Equity Research)
Will Novavax's ( NVAX ) Strategic Reshaping Curb Cash Burn?
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
In Article Trend: Neutral
April 11, 2024 (12:19) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International
UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
April 11, 2024 (11:48) / "Benzinga" (by Avi Kapoor)
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields - Patterson Cos ( NASDAQ:PDCO ) , GSK ( NYSE:GSK )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
In Article Trend: Neutral
April 11, 2024 (10:45) / "Benzinga" (by MarketBeat)
Pfizer Stock Rises on Upbeat RSV Vaccine Trial Data - Pfizer ( NYSE:PFE )
Pfizer Inc PFE stock is up 1.7% at $27.04 at last check, following news a late-stage trial of its respiratory syncytial virus ( RSV ) vaccine Abrysvo generated an immune response in higher risk adults under the age of 60. The company plans to seek expanded approval of the vaccine for ages 18 to ...
In Article Trend: Neutral
April 11, 2024 (10:18) / "CNBC" (by Annie Palmer)
Amazon CEO Andy Jassy says he's committed to cost cutting while investing in AI in shareholder letter
Andy Jassy pledged to keep looking for ways to cut costs even as the company doubles down on investing in new growth areas like artificial intelligence.
In Article Trend: Somewhat-Bullish
April 11, 2024 (08:21) / "The Financial Express" (by Health Desk)
Pfizer reports significant positive outcomes from phase 3 trial of its RSV vaccine
Drugmaker Pfizer has released that the data from the phase 3 clinical trial of its vaccine, Abrysvo for the treatment of severe respiratory syncytial virus ( RSV ) -associated lower respiratory tract disease ( LRTD ) .
In Article Trend: Neutral
April 10, 2024 (19:07) / "Zacks Commentary" (by Mark Vickery)
Top Analyst Reports for UnitedHealth, Pfizer & BlackRock
Today's Research Daily features new research reports on 12 major stocks, including UnitedHealth Group Incorporated (UNH), Pfizer Inc. (PFE) and BlackRock, Inc. (BLK).
In Article Trend: Somewhat-Bullish
April 10, 2024 (18:42) / "Benzinga" (by Vandana Singh)
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says - Vaxcyte ( NASDAQ:PCVX )
The global market study pneumococcal conjugate ( PCV ) market is ~$8 billion per year, and Vaxcyte Inc PCVX estimates it will grow to ~$12 billion in the next few years. The market is currently split into 25% adults / 75% infants.
In Article Trend: Somewhat-Bullish
April 10, 2024 (16:39) / "Money Morning" (by Chris Johnson)
There's a Stealth Rally Going on That Nobody is Talking About
Every week, I scan the charts of 23 different sector exchange-traded funds ( ETFs ) along with the leading companies from each. It's my way of making sure that I'm aware of what's going on in the less talked about areas of the market.
In Article Trend: Somewhat-Bullish
April 10, 2024 (14:47) / "Benzinga" (by Upwallstreet)
The Pharmaceutical Industry Finds Itself At A Historical Crossroads - Bristol-Myers Squibb ( NYSE:BMY )
Bristol Myers Squibb BMY, Merck & Co Inc MRK, Pfizer Inc PFE and Johnson & JohnsonJNJ are facing the so-called patent cliffs which imply revenue of tens of billions of dollars between now and and the end of this decade is at risk.
In Article Trend: Neutral
April 10, 2024 (13:26) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer's ( PFE ) RSV Vaccine Study in Adults Under 60 Meets Goal
Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.
In Article Trend: Somewhat-Bullish
April 10, 2024 (11:00) / "GlobeNewswire" (by Nurix Therapeutics)
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Extended the Strategic Collaboration with Gilead Sciences ...
In Article Trend: Neutral
April 10, 2024 (09:24) / "Benzinga" (by Benzinga Neuro)
PM Fumio Kishida Urges US Tech Giants To Invest In Japan: 'I'm Strongly Promoting Policies Toward The Next Economic Stage' - IBM ( NYSE:IBM ) , Boeing ( NYSE:BA )
In a strategic move to strengthen economic ties, Japanese Prime Minister Fumio Kishida has reached out to American business leaders, advocating for an uptick in technology investments within Japan.
In Article Trend: Somewhat-Bullish
April 10, 2024 (07:36) / "CNN" (by Juliana Liu)
Kishida US visit: Japan seeks investment in AI, semiconductors from American companies | Business
Japan seeks investment in AI, semiconductors from American companies ...
In Article Trend: Neutral
April 10, 2024 (07:36) / "CNN" (by Junko Ogura)
Japan seeks investment in AI, semiconductors from American companies | Business
Japan seeks investment in AI, semiconductors from American companies ...
In Article Trend: Neutral
April 10, 2024 (06:06) / "Motley Fool" (by David Jagielski)
Where Will Pfizer Stock Be in 10 Years?
Is this top healthcare stock a good buy for the long run?
In Article Trend: Somewhat-Bullish
April 9, 2024 (21:41) / "PR Newswire" (by DelveInsight Business Research)
Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
The tissue banking market is experiencing a surge in demand due to several factors: the growing prevalence and occurrence of chronic illnesses, the expanding elderly population susceptible to such ailments, and the potential breakthroughs in treating cancers, blood disorders, immune conditions, ...
In Article Trend: Somewhat-Bullish
April 9, 2024 (16:20) / "Benzinga" (by Vandana Singh)
Pfizer Seeks Expanded Use Of Abrysvo As Vaccine Shows Potential In 18+ Patients - Pfizer ( NYSE:PFE )
Tuesday, Pfizer Inc PFE released top-line immunogenicity and safety data from the ongoing pivotal Phase 3 MONeT trial, evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus ( RSV ) -associated lower respiratory ...
In Article Trend: Neutral
April 9, 2024 (14:47) / "Forbes" (by Ty Roush)
RSV Vaccine Could Protect High-Risk Adults Under 60, Pfizer Says
A late-stage trial of Pfizer's RSV vaccine showed promising results in adults under 60 years old, suggesting the shot could help people as young as 18, the company announced Tuesday, amid an effort to expand the vaccine's availability to more people who are at a higher risk to the potentially ...
In Article Trend: Neutral
April 9, 2024 (13:51) / "Motley Fool" (by Motley Fool Staff)
How's AT&T Handling Things?
We've also got a look at 3M's spinoff, gold prices, and the beef industry.
In Article Trend: Somewhat-Bullish
April 9, 2024 (12:15) / "Motley Fool" (by George Budwell)
2 Ultra-High-Yield Dividend Stocks to Buy and Hold Forever
A rate cut would likely be a boon for these two ultra-high yield dividend stocks.
In Article Trend: Somewhat-Bullish
April 9, 2024 (10:45) / "CNBC" (by Annika Kim Constantino)
Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.
In Article Trend: Neutral
April 9, 2024 (10:45) / "Motley Fool" (by Adam Spatacco)
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
In Article Trend: Somewhat-Bullish
April 9, 2024 (10:35) / "Motley Fool" (by Adria Cimino)
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These companies are close to launching new products that could supercharge revenue.
In Article Trend: Somewhat-Bullish
April 9, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
The current status of this stock might seem bleak. But like a chess grandmaster, Griffin is looking several moves ahead.
In Article Trend: Somewhat-Bullish
April 9, 2024 (08:50) / "Motley Fool" (by Adria Cimino)
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term.
In Article Trend: Bullish
April 8, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Declines More Than Market: Some Information for Investors
In the latest trading session, Pfizer (PFE) closed at $26.58, marking a -0.3% move from the previous day.
In Article Trend: Neutral
April 8, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
The growth of the giant-cell arteritis market is expected to be mainly driven by the growing geriatric population, the rise in the prevalence of cardiovascular disorders, technological advancements in the healthcare industry, and others.
In Article Trend: Somewhat-Bullish
April 8, 2024 (16:44) / "PR Newswire"
ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager - PR Newswire
ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager PR ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:15) / "Benzinga" (by Globe Newswire)
Dementia Drugs Market Size is projected to reach USD 26,795.69 million by 2030, growing at a CAGR of 7.95%: Straits Research
New York, United States, April 08, 2024 ( GLOBE NEWSWIRE ) -- Dementia is a term used to describe a group of symptoms that significantly impair memory, reasoning, and social abilities. The symptoms include cognitive and behavioral changes that worsen over time, making it difficult to perform even ...
In Article Trend: Neutral
April 8, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Is Trending Stock Pfizer Inc. ( PFE ) a Buy Now?
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
April 8, 2024 (12:36) / "Benzinga" (by Avi Kapoor)
Amazon, Alphabet And A Pharmaceutical Giant: CNBC's 'Final Trades' - Alphabet ( NASDAQ:GOOG ) , Amazon.com ( NASDAQ:AMZN )
On CNBC's "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners said Amazon.com, Inc. AMZN is on the cusp of an all-time high. Amazon.com is restarting construction of a 42-story office tower in Bellevue, a Seattle suburb, after halting work on 22 floors since 2022.
In Article Trend: Somewhat-Bullish
April 8, 2024 (11:45) / "CNBC" (by Christopher DiLella)
Record levels of funding propel Denver-Boulder to the top of the life sciences market
Denver-Boulder is rapidly becoming a life sciences hub thanks to a surge in funding, research collaborations and lab space.
In Article Trend: Somewhat-Bullish
April 8, 2024 (11:30) / "GlobeNewswire" (by XORTX Therapeutics Inc.)
XORTX Welcomes New Member to the Board of Directors
CALGARY, Alberta, April 08, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (11:30) / "Benzinga" (by Globe Newswire)
XORTX Welcomes New Member to the Board of Directors - Gamida Cell ( NASDAQ:GMDA )
CALGARY, Alberta, April 08, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) XRTXXRTXANUA ) ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (09:47) / "Motley Fool" (by Keith Speights)
This S&P 500 Dividend Stock Could Be the Best Bad-News Buy on the Market
There could be a light at the end of the tunnel for this beaten-down stock.
In Article Trend: Neutral
April 8, 2024 (09:06) / "Motley Fool" (by Sean Williams)
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead
Three highly successful billionaire money managers are paring down their respective stakes in artificial intelligence (AI) titan Nvidia and purchasing shares of six beaten-down value stocks.
In Article Trend: Neutral
April 8, 2024 (09:01) / "Money Control"
AstraZeneca, Daiichi drug gets broad tumor approval in US
The US Food and Drug Administration cleared the medicine for patients who have HER2-positive solid tumors that have spread or can't be removed with surgery, the company said. These patients have already received prior treatment and don't have any good alternatives.
In Article Trend: Somewhat-Bullish
April 7, 2024 (18:00) / "GlobeNewswire" (by BioNTech SE)
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
MAINZ, Germany, April 7, 2024 - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy ( "iNeST" ) candidate autogene cevumeran ( also known as BNT122, RO7198457 ...
In Article Trend: Neutral
April 7, 2024 (09:47) / "Motley Fool" (by Keith Speights)
My Top-5 Ultrahigh-Yield Dividend Stocks to Buy in April
Let April showers rain down dividends on you with these great stocks.
In Article Trend: Somewhat-Bullish
April 6, 2024 (10:49) / "Motley Fool" (by David Jagielski)
3 No-Brainer Dividend Stocks to Buy in April
Income investors will find a lot to like about these stocks.
In Article Trend: Somewhat-Bullish
April 6, 2024 (10:15) / "Motley Fool" (by Rachel Warren)
Got $1,000? 2 Phenomenal Growth Stocks to Buy in 2024 and Hold at Least a Decade
These stocks have unique buying propositions for long-term investors.
In Article Trend: Somewhat-Bullish
April 5, 2024 (18:32) / "Benzinga" (by Surbhi Jain)
Redditors Discuss What The Top 3 Value Stock Picks Are Right Now - Pfizer ( NYSE:PFE ) , Taiwan Semiconductor ( NYSE:TSM )
In the dynamic world of investing, uncovering value amidst market fluctuations is a quest pursued by many. Reddit's r/ValueInvesting community provides a unique platform where investors converge to share insights and identify potential opportunities.
In Article Trend: Bullish
April 5, 2024 (17:41) / "CNN"
Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts | Business
Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts ...
In Article Trend: Neutral
April 5, 2024 (17:28) / "Benzinga" (by Vandana Singh)
Pfizer's Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study - Pfizer ( NYSE:PFE )
Wednesday, the New England Journal of Medicine published full study data from the Phase 2/3 trial of Pfizer Inc's PFE Paxlovid ( Nirmatrelvir in combination with ritonavir ) . They shared initial data in 2022.
In Article Trend: Neutral
April 5, 2024 (15:02) / "PR Newswire" (by 360iResearch)
Antacids Market Projected to Reach $10.18 billion by 2030 - Exclusive Report by 360iResearch
PUNE, India, April 5, 2024 /PRNewswire/ -- The report titled "Antacids Market by Drug Class ( Acid Neutralizers, H2 Antagonist, Promotility Agents ) , Formulation ( Liquid, Powder, Tablet ) , Indication, Distribution Channel - Global Forecast 2024-2030" is now available on 360iResearch.com's ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (12:30) / "GlobeNewswire" (by IO Biotech)
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
NEW YORK, April 05, 2024 ( GLOBE NEWSWIRE ) -- IO Biotech ( Nasdaq: IOBT ) , a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's ...
In Article Trend: Neutral
April 5, 2024 (12:07) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.
In Article Trend: Neutral
April 5, 2024 (10:12) / "Motley Fool" (by Cory Renauer)
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
These stocks could outperform the broad market while they deliver heaps of dividend income.
In Article Trend: Somewhat-Bullish
April 4, 2024 (16:30) / "GlobeNewswire" (by GeoVax)
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Presentation Made During the 24th Annual World Vaccine Congress ...
In Article Trend: Neutral
April 4, 2024 (16:30) / "Benzinga" (by Globe Newswire)
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine - Geovax Labs ( NASDAQ:GOVXW ) , Geovax Labs ( NASDAQ:GOVX )
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 ( GLOBE NEWSWIRE ) -- via NewMediaWire -- GeoVax Labs, Inc.
In Article Trend: Neutral
April 4, 2024 (16:18) / "Benzinga" (by Vandana Singh)
CureVac, GS Partner Release Data On Influenza Vaccine Study - CureVac ( NASDAQ:CVAC ) , GSK ( NYSE:GSK )
CureVac N.V. CVAC released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate. The study is part of a collaboration with GSK Plc GSK.
In Article Trend: Neutral
April 4, 2024 (13:16) / "Benzinga" (by Vandana Singh)
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster - Sanofi ( NASDAQ:SNY )
Sanofi SA SASY has announced an agreement in principle to settle approximately 4,000 lawsuits in the United States linked to the discontinued heartburn drug Zantac. The company stated that the settlement encompasses many pending cases across various U.S. state courts, excluding Delaware.
In Article Trend: Neutral
April 4, 2024 (12:45) / "Benzinga" (by Globe Newswire)
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth
STUDIO CITY, Calif., April 04, 2024 ( GLOBE NEWSWIRE ) -- At the conclusion of this year's Myeloma Action Month, the International Myeloma Foundation ( IMF ) was truly grateful and overwhelmed by everyone's support in making the annual campaign a global success -with over 52 million reached in ...
In Article Trend: Bullish
April 4, 2024 (12:02) / "Canada Newswire" (by Pfizer Canada Inc.)
NURTEC ODT® is Now Available in Canada for the Treatment of Acute Migraine
More than one billion people worldwide live with migraine,i and the World Health Organization classifies migraine as the second leading cause of disability in the world.ii
In Article Trend: Neutral
April 4, 2024 (04:00) / "Financial Times"
FT ranking: The Americas' Fastest-Growing Companies 2024
The FT is pleased to announce its fifth annual ranking of the fastest-growing companies in the Americas, covering a period that took in the pandemic and the end of rock-bottom interest rates.
In Article Trend: Somewhat-Bullish
April 3, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Robust Growth Expected In The Intestinal Pseudo Obstruction Treatment Market: Market To Grow At A Rate Of More Than 5% Through 2024-2028 As Per TBRC's Intestinal Pseudo Obstruction Treatment Global Market Report 2024
LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Intestinal Pseudo Obstruction Treatment Global Market Report 2024, the intestinal pseudo obstruction treatment market has witnessed strong growth in recent years, with the market size projected to increase from ...
In Article Trend: Neutral
April 3, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
In Article Trend: Somewhat-Bullish
April 3, 2024 (02:47) / "PR Newswire" (by 360iResearch)
Contract Manufacturing Market Projected to Reach $604.11 billion by 2030 - Exclusive Report by 360iResearch
PUNE, India, April 2, 2024 /PRNewswire/ -- The report titled "Contract Manufacturing Market by Type ( End-to-End Manufacturing, Individual Component Manufacturing, Labor or Service Subcontracting ) , Services ( Custom Formulation, Manufacturing, Packaging ) , Verticals - Global Forecast ...
In Article Trend: Bullish
April 2, 2024 (18:54) / "Benzinga" (by Vandana Singh)
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race - AstraZeneca ( NASDAQ:AZN )
AstraZeneca Plc's AZN Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a sales target of $45 billion by 2023, a goal set a decade ago amid pressure from U.S. rival Pfizer Inc PFE.
In Article Trend: Somewhat-Bullish
April 2, 2024 (14:40) / "Benzinga" (by Globe Newswire)
Cytokine Market Size is projected to reach USD 148.56 billion by 2031, growing at a CAGR of 8.40%: Straits Research
New York, United States, April 02, 2024 ( GLOBE NEWSWIRE ) -- A cytokine is a collection of proteins, peptides, or glycoproteins released by particular cells to regulate the development and function of the immune system and blood cells.
In Article Trend: Neutral
April 2, 2024 (14:17) / "Benzinga" (by Upwallstreet)
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era - Pfizer ( NYSE:PFE )
Pfizer PFE and Moderna MRNA did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. But, in a post-pandemic world, Pfizer and Moderna shares lost about 30% of their respective value over the past year.
In Article Trend: Neutral
April 2, 2024 (14:15) / "Motley Fool" (by Prosper Junior Bakiny)
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague
These stocks could move in very different directions over the long run.
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
In Article Trend: Bullish
April 2, 2024 (11:00) / "Forbes" (by Trefis Team)
After A 30% Fall In A Year, Is Pfizer Stock A Better Pick Over Merck?
Given its attractive valuation, we believe Pfizer stock ( NYSE: PFE ) is a better pick than its peer - Merck stock ( NYSE: MRK ) . MRK trades at a higher valuation multiple of 5.6x revenues vs. 2.7x for PFE, due to its superior revenue growth over the last year and a better financial position.
In Article Trend: Somewhat-Bullish
April 2, 2024 (09:21) / "Motley Fool" (by Sean Williams)
3 Magnificent Ultra-High-Yield Dividend Stocks That Are Screamings Buys in April
These supercharged dividend stocks -- sporting an average yield of 9.02% -- can pack a punch for income investors' pocketbooks.
In Article Trend: Somewhat-Bullish
April 1, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Stock Moves -0.11%: What You Should Know
In the latest trading session, Pfizer (PFE) closed at $27.72, marking a -0.11% move from the previous day.
In Article Trend: Somewhat-Bullish
April 1, 2024 (16:46) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers' ( BMY ) Zeposia Fails Crohn's Disease Study
Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.
In Article Trend: Neutral
April 1, 2024 (14:15) / "Motley Fool" (by Prosper Junior Bakiny)
2 Stocks Down 30% and 27% to Buy and Hold
Look beyond these companies' challenges.
In Article Trend: Somewhat-Bullish
April 1, 2024 (13:29) / "CNN" (by Eva Rothenberg)
US scientists are leaving academia. That's bad news for drug companies | Business
US scientists are leaving academia. That's bad news for drug companies ...
In Article Trend: Neutral
April 1, 2024 (13:00) / "Benzinga" (by Avi Kapoor)
Jim Cramer Says Chevron Is Doing 'Pretty Well,' Will Give This Pharma Giant 'A Chance' - Core & Main ( NYSE:CNM ) , Chevron ( NYSE:CVX )
On CNBC's "Mad Money Lightning Round," Jim Cramer said Core & Main, Inc. CNM is "right at the heart of this infrastructure bull market I keep talking about because it does waste water. It is perfectly positioned…even though it's just been a horse, it can go higher."
In Article Trend: Somewhat-Bullish
April 1, 2024 (09:05) / "Motley Fool" (by Adria Cimino)
Better Recovery Story Buy: Pfizer vs Moderna
Pfizer and Moderna each have slipped about 30% over the past year.
In Article Trend: Somewhat-Bullish
March 31, 2024 (13:31) / "Motley Fool" (by Adam Spatacco)
Prediction: Pfizer Won't Acquire Viking Therapeutics. Here's Why.
Viking Therapeutics may be the next company to enter the red-hot weight loss space.
In Article Trend: Neutral
March 30, 2024 (11:45) / "Motley Fool" (by Motley Fool Staff)
Market Cap Game Show: Andy Cross vs. Bill Mann
Join the "Rule Breaker Investing" fun.
In Article Trend: Somewhat-Bullish
March 29, 2024 (14:30) / "PR Newswire" (by Unifi Service)
Unifi Aviation commits to hiring 500 refugees by 2027
Company launched refugee hiring program in 2021, has 200+ refugees working airport operations in multiple states ATLANTA, March 29, 2024 /PRNewswire/ -- Unifi Aviation is making a pledge to employ 500 refugees over the next three years, a commitment the company made at the second annual TENT U.S.
In Article Trend: Somewhat-Bullish
March 29, 2024 (13:38) / "PR Newswire" (by The Kinetix Group)
The Kinetix Group and Pfizer Health Equity Work Recognized by PM360
NEW YORK, March 29, 2024 /PRNewswire/ -- The Kinetix Group ( TKG ) and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative. The award recognized Pfizer's atopic dermatitis interactive guide for varying skin tones.
In Article Trend: Bullish
March 29, 2024 (13:15) / "Motley Fool" (by David Jagielski)
Is It Too Late to Buy Viking Therapeutics Stock?
Shares of Viking Therapeutics have skyrocketed more than 350% this year.
In Article Trend: Somewhat-Bullish
March 28, 2024 (13:50) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:15) / "Motley Fool" (by Prosper Junior Bakiny)
Is Bristol Myers Squibb Stock a Buy?
The company is going through a rough patch.
In Article Trend: Neutral
)
March 28, 2024 (03:12) / "Business Standard" (by Reuters)
J&J can contest evidence linking its talc to ovarian cancer, says US judge
Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S.
In Article Trend: Neutral
March 27, 2024 (17:46) / "Benzinga" (by Benzinga Insights)
Pfizer's Options: A Look at What the Big Money is Thinking - Pfizer ( NYSE:PFE )
Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer PFE revealed 15 unusual trades. Delving into the details, we found 66% of traders were bullish, while 33% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Posts Upbeat Data From Next-Gen COVID Jab Study
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
In Article Trend: Neutral
March 27, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Biochemical Market Shows Strong Growth Potential, Propelled by Demand for Bio-Based Products As Per The Business Research Company's Biochemical Global Market Report 2024
LONDON, March 27, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's biochemical global market report 2024, the biochemical market is poised for robust expansion in the coming years, driven by a burgeoning demand for bio-based products worldwide.
In Article Trend: Somewhat-Bullish
March 27, 2024 (14:12) / "The Economist" (by The Economist)
Who is up and who is down on China's economic team
O 27 , when Xi Jinping met American business executives in Beijing, it was a rare opportunity for these corporate bigwigs to interact with China's leader on his home turf. The meeting followed the China Development Forum, an annual economic conference held amid the lakes and willows of a tranquil ...
In Article Trend: Neutral
March 27, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Is Most-Watched Stock Pfizer Inc. ( PFE ) Worth Betting on Now?
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
March 27, 2024 (11:00) / "GlobeNewswire" (by iBio)
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
- Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (11:00) / "Benzinga" (by Globe Newswire)
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases - iBio ( AMEX:IBIO )
- Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments - - iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets -
In Article Trend: Somewhat-Bullish
March 27, 2024 (08:50) / "Motley Fool" (by Adria Cimino)
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000
Each of these three companies are entering a new era of growth.
In Article Trend: Somewhat-Bullish
March 26, 2024 (21:04) / "GlobeNewswire" (by Serina Therapeutics)
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
HUNTSVILLE, Ala., March 26, 2024 ( GLOBE NEWSWIRE ) -- Serina Therapeutics ( NYSE American: SER ) , a clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases, today announced the closing of its previously ...
In Article Trend: Neutral
March 26, 2024 (18:00) / "PR Newswire" (by Research and Markets)
Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie, AstraZeneca, Merck & Co., Novartis, Pfizer and more
Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (15:25) / "CNBC" (by Annika Kim Constantino)
Moderna says new Covid vaccine showed stronger immune response than current shot in study
Moderna's new shot offers the potential of a longer shelf life and is one component of its combination vaccine targeting Covid and the flu.
In Article Trend: Neutral
March 26, 2024 (08:17) / "Motley Fool" (by Cory Renauer)
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold Forever
If you have a Benjamin burning a hole in your pocket, these stocks are a great way to invest it.
In Article Trend: Somewhat-Bullish
March 26, 2024 (06:00) / "Benzinga" (by Globe Newswire)
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain ( France ) , March 26, 2024 - Valneva SE VALNVLA, a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika ...
In Article Trend: Neutral
March 26, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain ( France ) , March 26, 2024 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the ...
In Article Trend: Neutral
)
March 26, 2024 (04:24) / "Business Standard" (by Bloomberg)
US CEOs extend China stay after last-minute invite to meet Prez Xi Jinping
Some US executives in Beijing for a business summit are rejigging their long-planned schedules after receiving an invite to a Wednesday meeting with a top Chinese leader - widely expected to be President Xi Jinping.
In Article Trend: Neutral
)
March 26, 2024 (03:35) / "Business Standard" (by Bloomberg)
Tim Cook's love for China helps Xi Jinping fight fears of economic slump
Tim Cook during the opening of the new Apple Store in Shanghai on March 21. Photographer: Qilai Shen/Bloomberg Days after he opened an expansive new retail store in Shanghai and pledged a fresh investment in applied research in the country, Apple Inc.
In Article Trend: Somewhat-Bullish
March 26, 2024 (00:53) / "Forbes" (by Christian B. Miller)
Getting More Impatient When The End Is In Sight: Taylor Swift's New Album, COVID Vaccines, And The 2020 Presidential Election
Like millions of her fans, you might be waiting impatiently for Taylor Swift's new album, The Tortured Poets Department, to drop. You know what the release date is. As the big day draws near, do you find your level of impatience going up, going down, or staying roughly the same?
In Article Trend: Neutral
March 25, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Gains As Market Dips: What You Should Know
Pfizer (PFE) closed the most recent trading day at $27.43, moving +0.26% from the previous trading session.
In Article Trend: Neutral
March 25, 2024 (14:05) / "Zacks Commentary" (by Zacks Equity Research)
Bayer ( BAYRY ) Banks on Pipeline Progress Amid Challenges
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
In Article Trend: Neutral
March 25, 2024 (11:30) / "GlobeNewswire" (by SIGA Technologies Inc.)
SIGA Names Larry Miller General Counsel
NEW YORK, March 25, 2024 ( GLOBE NEWSWIRE ) -- SIGA Technologies, Inc. ( NASDAQ: SIGA ) , a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today.
In Article Trend: Neutral
March 25, 2024 (11:30) / "Benzinga" (by Globe Newswire)
SIGA Names Larry Miller General Counsel - SIGA Technologies ( NASDAQ:SIGA )
NEW YORK, March 25, 2024 ( GLOBE NEWSWIRE ) -- SIGA Technologies, Inc. SIGA, a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today.
In Article Trend: Neutral
March 25, 2024 (11:00) / "Forbes" (by Dmitry Reykhart)
Council Post: What's Driving Big Pharma's Recent Market Performance?
What's Driving Big Pharma's Recent Market Performance? Forbes ...
In Article Trend: Neutral
March 25, 2024 (10:25) / "Motley Fool" (by Adam Spatacco)
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants.
In Article Trend: Somewhat-Bullish
March 25, 2024 (09:51) / "Motley Fool" (by Keith Speights)
3 Ultra-High-Yield Dividend Stocks That Could Realistically Double Your Money by 2030
There's no guarantee these stocks can generate 100% returns by 2030. But they have a clear path to make it happen.
In Article Trend: Somewhat-Bullish
March 25, 2024 (08:50) / "Motley Fool" (by Keith Speights)
Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?
What's good for Wood and Ark Invest might not be good for other investors.
In Article Trend: Somewhat-Bullish
March 25, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
Saint-Herblain ( France ) , March 25, 2024 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document ( URD ) with the French Financial Markets Authority ( AMF ) under the filing ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (06:00) / "Business Insider" (by markets.businessinsider.com)
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
Valneva Announces Filing of 2023 Universal Registration Document and US Form ...
In Article Trend: Somewhat-Bullish
March 24, 2024 (12:00) / "CNBC" (by Annika Kim Constantino)
Amgen wants in on the booming weight loss drug market - and it's taking a different approach
Amgen is testing a monthly injection that works differently and appears to help patients maintain their weight loss even after they stop taking it.
In Article Trend: Neutral
March 23, 2024 (10:45) / "Motley Fool" (by Keith Speights)
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks.
In Article Trend: Somewhat-Bullish
March 23, 2024 (09:50) / "Motley Fool" (by Keith Speights and Adria Cimino)
A Bull Market Is Here: 2 Magnificent Stocks Down 30% or More to Buy Right Now
These stocks share several things in common.
In Article Trend: Somewhat-Bullish
March 23, 2024 (09:43) / "Motley Fool" (by Cory Renauer)
2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?
After a lousy year of declining prices, these stocks offer yields of 4.7% and 6.1% at recent prices.
In Article Trend: Somewhat-Bullish
March 23, 2024 (08:30) / "Motley Fool" (by Keith Speights)
Will Pfizer Be a Trillion-Dollar Stock by 2035?
A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable.
In Article Trend: Neutral
)
March 23, 2024 (02:40) / "Business Standard" (by Bloomberg)
China relaxes rules governing cross-border data flows on business pressure
Data collected in international trade, cross-border travel, manufacturing, academic research, and marketing that don't contain either personal information or "important" information will be exempt from security evaluations when transfered out of the country, China's top internet regulator said ...
In Article Trend: Neutral
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (16:00) / "PR Newswire" (by Research and Markets)
Vaccine Market Insights Revealed in New 2024 Global Industry Report
DUBLIN, March 22, 2024 /PRNewswire/ -- The "The World Market for Vaccines, 2024" report has been added to ResearchAndMarkets.com's offering. The healthcare landscape is ever-evolving, and as infectious diseases continue to be a global concern, the vaccine market remains a critical area of focus ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (15:59) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
In Article Trend: Neutral
March 22, 2024 (14:34) / "Benzinga" (by Vandana Singh)
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co LLY and Novo Nordisk A/S NVS, alleging severe complications after taking their medications to manage diabetes and aid weight loss.
In Article Trend: Neutral
March 22, 2024 (10:15) / "Motley Fool" (by Prosper Junior Bakiny)
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
The mid-cap biotech has succeeded where many others failed.
In Article Trend: Neutral
March 21, 2024 (19:38) / "Forbes" (by GuruFocus)
Pfizer Is Too Cheap To Ignore
The health care giant has rarely been this cheap in the recent past • Pfizer is currently faced with the reality of a few patent expiries in the coming years, which are likely to have a notable impact on revenue. • With some of Pfizer's blockbuster drugs facing IP expirations, the company's ...
In Article Trend: Somewhat-Bullish
March 21, 2024 (16:36) / "Benzinga" (by Vandana Singh)
Spinal Delivery Of Taysha's Gene Therapy Shows Promise In Rare Childhood Neurodegenerative Disease - Taysha Gene Therapies ( NASDAQ:TSHA )
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy ( GAN ) , that begins in early childhood was well tolerated and showed signs of therapeutic benefit in a Phase 1 trial led by the National Institutes of Health ( NIH ) .
In Article Trend: Neutral
March 21, 2024 (15:31) / "Benzinga" (by Benzinga Insights)
Pfizer Options Trading: A Deep Dive into Market Sentiment - Pfizer ( NYSE:PFE )
Deep-pocketed investors have adopted a bearish approach towards Pfizer PFE, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Neutral
March 21, 2024 (11:55) / "Zacks Commentary" (by Zacks Equity Research)
Cardiff ( CRDF ) Stock Rallies 194% in a Month: Here's Why
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
In Article Trend: Somewhat-Bullish
March 21, 2024 (11:30) / "Motley Fool" (by David Jagielski)
Is Pfizer the Best Dividend Stock for You?
Pfizer's stock is cheap, and it pays an incredibly high yield right now.
In Article Trend: Somewhat-Bullish
March 21, 2024 (10:00) / "Benzinga" (by Shanthi Rexaline)
Is Cathie Wood Buying The Rumor? Ark More Than Doubles Stake In This COVID-19 Vaccine Maker Ahead Of Flurry Of Catalysts - Moderna ( NASDAQ:MRNA )
Money manager Cathie Wood's Ark Invest has a favorite biotech holding now, going by the firm's recent buying activity. What Happened: Ark, through its flagship Ark Innovation ETF ARKK and Ark Genomic Revolution ETF ARKG, has been brisk with its acquisition of Moderna, Inc. MRNA shares in March.
In Article Trend: Somewhat-Bullish
March 21, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
Saint-Herblain ( France ) , March 21, 2024 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ®, moderate a roundtable on the Zika and chikungunya viruses, and participate in a panel ...
In Article Trend: Somewhat-Bullish
March 21, 2024 (06:00) / "Benzinga" (by Globe Newswire)
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
Saint-Herblain ( France ) , March 21, 2024 - Valneva SE VALNVLA, a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ®, moderate a roundtable on the Zika and chikungunya viruses, and participate in a panel discussion on efforts to eradicate ...
In Article Trend: Somewhat-Bullish
March 20, 2024 (18:45) / "Motley Fool" (by Motley Fool Transcribing)
BioNTech Se ( BNTX ) Q4 2023 Earnings Call Transcript
BNTX earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
March 20, 2024 (17:38) / "Benzinga" (by Upwallstreet)
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials - BioNTech ( NASDAQ:BNTX )
BioNTech SE BNTX is way past its glorious Covid-19 days, when it thrived with Pfizer Inc PFE for saving the world from the pandemic with their jointly developed vaccine.
In Article Trend: Neutral
March 20, 2024 (17:07) / "Investors Business Daily" (by Investor's Business Daily)
Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?
Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...
In Article Trend: Neutral
March 20, 2024 (15:49) / "Benzinga" (by Henry Khederian)
Why Moderna Shares Are Falling - Moderna ( NASDAQ:MRNA )
Moderna Inc MRNA shares are trading lower by 2.7% to $102.25 during Wednesday's session in possible sympathy with BioNTech, which reported worse than expected fourth-quarter earnings. In the fourth-quarter of fiscal year 2023 BioNTech SE reported lower earnings and sales than the previous year.
In Article Trend: Neutral
March 20, 2024 (15:44) / "Zacks Commentary" (by Zacks Equity Research)
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
In Article Trend: Somewhat-Bullish
March 20, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Migraine Drugs Market Continues To Surge At A Rate Of More Than 6%, Fueled By Innovation And Demand As Per The Business Research Company's Migraine Drugs Global Market Report 2024
LONDON, March 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Migraine Drugs Global Market Report 2024, the migraine drugs market has experienced robust growth in recent years, with promising projections for the future.
In Article Trend: Bullish
March 20, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Interstitial Cystitis Drugs Market Witnesses Robust Growth, Predicted To Surge At A Rate Of More Than 5% Through 2024-2028 As Per The Business Research Company's Interstitial Cystitis Drugs Global Market Report 2024
LONDON, March 20, 2024 ( GLOBE NEWSWIRE ) -- The Business Research Company's Interstitial Cystitis Drugs Global Market Report 2024, the interstitial cystitis drugs market has experienced significant growth in recent years, with notable projections indicating continued expansion.
In Article Trend: Bullish
March 20, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Ischemic Heart Disease ( IHD ) Drugs Market Overview 2024-2028: Projected Market Size, Major Drivers And Leading Segments As Per The Business Research Company's Ischemic Heart Disease ( IHD ) Drugs Global Market Report 2024
LONDON, March 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Ischemic Heart Disease ( IHD ) Drugs Global Market Report 2024, the ischemic heart disease ( IHD ) drugs market has demonstrated substantial growth in recent years, with promising projections for the future.
In Article Trend: Bullish
March 20, 2024 (13:09) / "Investors Business Daily" (by Investor's Business Daily)
BioNTech Dives As Sales Crash 65%, Missing Forecasts
BioNTech Stock Dives After Sales Plummet 65% And Miss Forecasts Investor's Business Daily ...
In Article Trend: Neutral
March 20, 2024 (13:03) / "Benzinga" (by Globe Newswire)
Alation Appoints Yvonne Wassenaar to its Board of Directors
REDWOOD CITY, Calif., March 20, 2024 ( GLOBE NEWSWIRE ) -- Alation, Inc., the data intelligence company, today announced the appointment of Yvonne Wassenaar to its Board of Directors. She brings more than 30 years of experience scaling AI, cloud, and SaaS companies globally.
In Article Trend: Bullish
March 20, 2024 (12:43) / "Benzinga" (by Vandana Singh)
Why Is BioNTech Stock Trading Lower On Wednesday? - BioNTech ( NASDAQ:BNTX )
Pfizer Inc's PFE German partner, BioNTech SE BNTX, reported fourth-quarter 2023 EPS of fiscal year Q4 GAAP EPS of €1.90 versus €9.26, a year ago, equivalent to $2.04 missing the consensus of $2.64.
In Article Trend: Neutral
March 20, 2024 (11:44) / "Barrons" (by Brian Swint)
BioNTech Earnings Miss Estimates. The Stock Falls and Also Drags Moderna Lower.
BioNTech Earnings Fall Short of Estimates. The Stock Is Down. ...
In Article Trend: Somewhat-Bearish
March 20, 2024 (11:30) / "GlobeNewswire" (by Vera Therapeutics)
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
BRISBANE, Calif., March 20, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights ...
In Article Trend: Neutral
March 20, 2024 (10:15) / "GlobeNewswire" (by BioNTech SE)
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
• Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 • Aiming for first oncology launch in 2026 and ten indication approvals by 2030 as part of BioNTech's strategy to develop combinatorial and ...
In Article Trend: Neutral
March 20, 2024 (10:00) / "GlobeNewswire" (by BioNTech SE)
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
Mainz, Germany, March 20, 2024 ( GLOBE NEWSWIRE ) - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
In Article Trend: Somewhat-Bullish
March 20, 2024 (08:42) / "Barrons" (by Joe Woelfel)
Intel, Chipotle, Nvidia, PDD, Mobileye, Signet, BioNTech, and More Stock Market Movers
Chipotle, Nvidia, JetBlue, Micron, Gildan Activewear, and More Stock Market Movers ...
In Article Trend: Somewhat-Bullish
)
March 20, 2024 (06:09) / "Business Standard" (by AP)
Probes target Bolsonaro, but his Covid decisions catching up to him first
As Brazilian President Jair Bolsonaro's term wound down in the final days of December 2022, he had decided to skip the ritual of handing over the presidential sash to his successor, and instead made plans to travel abroad.
In Article Trend: Somewhat-Bearish
March 20, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
Total revenues of €153.7 million, including product sales of €144.6 million ...
In Article Trend: Somewhat-Bullish
March 20, 2024 (06:00) / "Business Insider" (by markets.businessinsider.com)
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
Product sales surpassed pre-pandemic ( 2019 ) sales by 12% and 2022 sales by 26% Excluding COVID-19 vaccine sales, product sales grew by 63% compared to 2022 Cash position of €126.1 million at year-end 2023 enhanced by €95 million from sale of Priority Review Voucher ( PRV ) 1
In Article Trend: Somewhat-Bullish
March 20, 2024 (04:10) / "Associated Press" (by ELÉONORE HUGHES)
Several probes target Brazil's Bolsonaro, but his COVID decisions are catching up to him first
RIO DE JANEIRO ( AP ) - As Brazilian President Jair Bolsonaro's term wound down in the final days of December 2022, he had decided to skip the ritual of handing over the presidential sash to his successor, and instead made plans to travel abroad.
In Article Trend: Somewhat-Bearish
March 19, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) closed at $27.63 in the latest trading session, marking a -0.32% move from the prior day.
In Article Trend: Somewhat-Bullish
March 19, 2024 (18:05) / "Canada Newswire"
Innovative Medicines Canada welcomes Bettina Hamelin as new President - Canada NewsWire
Innovative Medicines Canada welcomes Bettina Hamelin as new President Canada ...
In Article Trend: Bullish
March 19, 2024 (15:08) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) to Decrease Stake in Haleon From 32% to 24%
Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.
In Article Trend: Neutral
March 19, 2024 (14:39) / "Associated Press" (by MAURICIO SAVARESE)
Brazil's Bolsonaro is indicted for first time over alleged falsification of his own vaccination data
SAO PAULO ( AP ) - Former Brazilian President Jair Bolsonaro was formally accused Tuesday of falsifying his COVID-19 vaccination data, marking the first indictment for the embattled far-right leader, with more allegations potentially in store.
In Article Trend: Neutral
March 19, 2024 (12:30) / "PR Newswire" (by Flagship Pioneering)
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
Ranked #3 Most Innovative Company in North America Recognized for the Third Consecutive Year CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of ...
In Article Trend: Bullish
March 19, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer - Conduit Pharmaceuticals ( NASDAQ:CDT )
Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value
In Article Trend: Somewhat-Bullish
March 19, 2024 (09:01) / "Business Standard" (by Capital Market)
Nifty below 22,850 mark; pharma shares decline
Nifty below 22,850 mark. pharma shares decline Business Standard ...
In Article Trend: Neutral
March 18, 2024 (21:39) / "Forbes" (by Joshua Cohen)
New Non-Opioid Pain Meds Hold Promise, But Face Clinical Development And Insurer Challenges
Vertex Pharmaceuticals recently released late-stage trial results for an investigational non-opioid pain medication showing it was safe and efficacious while offering modest pain relief. Pain impacts tens of millions of Americans on a daily basis.
In Article Trend: Neutral
March 18, 2024 (20:40) / "Benzinga" (by Globe Newswire)
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - Arvinas ( NASDAQ:ARVN )
NEW HAVEN, Conn., March 18, 2024 ( GLOBE NEWSWIRE ) -- Arvinas, Inc.
In Article Trend: Somewhat-Bullish
March 18, 2024 (20:40) / "GlobeNewswire" (by Arvinas Inc.)
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635 ( c ) ( 4 ) - - Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635 ( c ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (19:16) / "Benzinga" (by Globe Newswire)
Carmell to Host Investor Webinar, "Unveiling the Secretome: On the Eve of Product Launch" Featuring Key Opinion Leaders in the Medical Aesthetics Field - Carmell ( NASDAQ:CTCX )
PITTSBURGH, March 18, 2024 ( GLOBE NEWSWIRE ) -- Carmell Corporation CTCX, a bio-aesthetics company focused on skin and hair health ( "Carmell" or the "Company" ) , today announced it will host an Investor Webinar titled "Unveiling the Secretome: On the Eve of Product Launch" on March 20, 2024 ...
In Article Trend: Neutral
March 18, 2024 (19:16) / "GlobeNewswire" (by Carmell Corporation)
Carmell to Host Investor Webinar, "Unveiling the Secretome: On the Eve of Product Launch" Featuring Key Opinion Leaders in the Medical Aesthetics Field
Carmell to host an Investor Webinar titled "Unveiling the Secretome: On the Eve of Product Launch" ...
In Article Trend: Neutral
March 18, 2024 (16:08) / "Benzinga" (by Vandana Singh)
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B - Haleon ( NYSE:HLN ) , Pfizer ( NYSE:PFE )
Pfizer Inc PFE plans to slash its stake to approximately 24% in Consumer healthcare giant Haleon Plc HLN This move follows Pfizer's earlier announcement that it will gradually divest its ownership in Haleon. The offer price per share is set to be disclosed around March 19, after a book-building ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (12:45) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights Microsoft, Coca-Cola, Accenture, Applied Materials and Pfizer
Microsoft, Coca-Cola, Accenture, Applied Materials and Pfizer are included in this Analyst Blog.
In Article Trend: Somewhat-Bullish
March 18, 2024 (09:49) / "Motley Fool" (by Keith Speights)
5 Reasons Why Buying This 6%-Yielding Dividend Stock Could Be a Brilliant Move
Pfizer just might be one of the biggest comeback stories of the second half of this decade.
In Article Trend: Neutral
March 18, 2024 (09:36) / "PR Newswire"
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... PR ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (07:00) / "GlobeNewswire" (by Lacroix Group)
LACROIX and AIAC finalize the sale/ acquisition of the Road Signs Business Unit.
LACROIX and AIAC finalize the sale/ acquisition LACROIX announces the sale of its Road Signs Business Unit to the industrial investment company AIAC ( American Industrial Acquisition Corporation ) , following on from the exclusive negotiations announced between the two companies on December 14.
In Article Trend: Somewhat-Bullish
March 18, 2024 (06:00) / "Benzinga" (by Globe Newswire)
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
Reimbursements deferred by 18 months to start in January 2026 instead of July 2024
In Article Trend: Somewhat-Bullish
March 18, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
Saint-Herblain ( France ) , March 18, 2024 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced an agreement with funds managed by leading U.S. healthcare investment firms Deerfield Management Company and OrbiMed to extend the interest-only period of ...
In Article Trend: Neutral
March 17, 2024 (18:28) / "Motley Fool" (by Prosper Junior Bakiny)
Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be
The drugmaker is magnificent in its own right.
In Article Trend: Somewhat-Bullish
March 17, 2024 (17:09) / "Benzinga" (by Globe Newswire)
Pidilizumab Clinical Trials Bispecific Antibodies Market Report 2029
Delhi, March 17, 2024 ( GLOBE NEWSWIRE ) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: > USD 36 Billion Insight On Bispecific Antibodies In Clinical Trials: > 600 Bispecific Antibodies
In Article Trend: Neutral
March 16, 2024 (12:17) / "Motley Fool" (by David Jagielski)
Will Viking Therapeutics Get Acquired?
Would an acquisition be good news for Viking Therapeutics investors?
In Article Trend: Somewhat-Bullish
March 16, 2024 (09:51) / "Motley Fool" (by Keith Speights)
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These stocks could be cheap only for a season.
In Article Trend: Somewhat-Bullish
March 15, 2024 (21:07) / "Motley Fool" (by Alex Carchidi)
Is Ginkgo Bioworks Stock a Buy?
There's a lot to like about this business, but it's still a risky bet.
In Article Trend: Neutral
March 15, 2024 (20:29) / "Business Insider" (by Vandana Singh)
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
Thursday, Immuneering Corporation ( NASDAQ:IMRX ) revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-1-104 in advanced RAS-mutant solid tumors. Friday, shares are trading lower after several analysts downgraded the stock after the company released the data.
In Article Trend: Neutral
March 15, 2024 (19:29) / "Benzinga" (by Vandana Singh)
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data - Immuneering ( NASDAQ:IMRX )
Thursday, Immuneering Corporation IMRX revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-1-104 in advanced RAS-mutant solid tumors. Friday, shares are trading lower after several analysts downgraded the stock after the company released the data.
In Article Trend: Somewhat-Bullish
March 15, 2024 (18:33) / "CNBC" (by Michelle Fox)
This overlooked corner of women's health could be a $350 billion market opportunity
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
In Article Trend: Neutral
)
March 15, 2024 (16:39) / "Business Standard" (by Press Trust of India)
Lupin gets USFDA nod to market a generic drug to treat bacterial infections
Drug maker Lupin on Friday said it has received approval from the US health regulator to market a generic medication to treat bacterial infections, in America. The company has received approval from the USFDA for Doxycycline for Injection USP, the Mumbai-based drug maker said in a statement.
In Article Trend: Neutral
March 15, 2024 (16:31) / "Benzinga" (by Benzinga Insights)
Decoding Pfizer's Options Activity: What's the Big Picture? - Pfizer ( NYSE:PFE )
Investors with a lot of money to spend have taken a bearish stance on Pfizer PFE. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Neutral
March 15, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)
Monoclonal Antibody ( mABs ) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:37) / "Benzinga" (by PR.com)
Sabina Ewing Awarded Bench and Deloitte Inaugural Life Sciences Tech Innovation Award
San Diego, CA March 15, 2024 -- ( PR.com ) -- Bench International, a leading global executive search firm, is pleased to announce Sabina Ewing, Senior Vice President, Business & Technology Services and Chief Information Officer at Abbott, is the recipient of the inaugural Bench and Deloitte Life ...
In Article Trend: Bullish
March 15, 2024 (13:30) / "Motley Fool" (by David Jagielski)
Is Pfizer Stock a Millionaire Maker?
A couple of years ago, Pfizer's shares may have seemed like a sure thing. That may not be the case anymore.
In Article Trend: Neutral
March 15, 2024 (13:19) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer Inc. ( PFE ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
March 15, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer.
In Article Trend: Neutral
March 14, 2024 (20:03) / "Benzinga" (by Vandana Singh)
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus - AstraZeneca ( NASDAQ:AZN ) , Johnson & Johnson ( NYSE:JNJ )
Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization ( BIO ) , a U.S. industry lobbying group, severs ties with the Chinese biotech.
In Article Trend: Neutral
March 14, 2024 (18:48) / "Benzinga" (by The Bamboo Works)
Stock Disconnect Triggers Investor Exodus From CStone Pharma - Zai Lab ( NASDAQ:ZLAB )
CEO Jason Yang has increased his CStone stake multiple times over the past 18 months to 4.79% of outstanding shares, signaling confidence in the company The drug developer slimmed down its operations last year and licensed out several products, switching its focus to R&D and widening the approved ...
In Article Trend: Neutral
March 14, 2024 (14:30) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Gets EU Nod for Expanded Use of Pneumococcal Jab
Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:53) / "Motley Fool" (by David Jagielski)
Is Viatris a Great Dividend Stock or Just a Value Trap?
Investors can collect a high yield with Viatris, but is it a risky payout to rely on?
In Article Trend: Neutral
March 14, 2024 (12:27) / "Benzinga" (by Avi Kapoor)
How To Earn $500 A Month From Pfizer Stock - Pfizer ( NYSE:PFE )
Pfizer Inc. PFE shares closed slightly higher on Wednesday. The New York-based pharmaceutical giant recently said that the European Commission approved PREVNAR 20, a caccine to help protect infants and children against pneumococcal disease.
In Article Trend: Somewhat-Bullish
March 14, 2024 (10:50) / "PR Newswire" (by Inc.)
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Company to host conference call and webcast today at 8:30 a.m. EDT
In Article Trend: Neutral
March 14, 2024 (10:50) / "PR Newswire" (by Protalix BioTherapeutics)
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Company to host conference call and webcast today at 8:30 a.m. EDT
In Article Trend: Neutral
March 14, 2024 (09:25) / "Motley Fool" (by James Brumley)
3 Stocks I'm Adding to My Retirement Account in March
A handful of names offer a combination of reliability and opportunity that many other stocks don't right now.
In Article Trend: Somewhat-Bullish
March 13, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Pfizer (PFE) stood at $28.22, denoting a +0.75% change from the preceding trading day.
In Article Trend: Somewhat-Bullish
March 13, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Chronic Myeloid Leukemia Treatment Market On A Growth Trajectory: Market Size To Reach $12 Billion By 2028 As Per The Business Research Company's Chronic Myeloid Leukemia Treatment Global Market Report 2024
LONDON, March 13, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Chronic Myeloid Leukemia Treatment Global Market Report 2024, the chronic myeloid leukemia treatment market has witnessed robust growth in recent years, and projections indicate a continued upward trajectory.
In Article Trend: Somewhat-Bullish
March 13, 2024 (13:54) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer's ( PFE ) Adcetris Meets Survival Goal in Lymphoma Study
Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.
In Article Trend: Somewhat-Bullish
March 13, 2024 (13:25) / "Benzinga" (by Avi Kapoor)
Will Alphabet 'Storm Back?' Plus: Progressive, D.R. Horton And Pfizer On CNBC's 'Final Trades' - Alphabet ( NASDAQ:GOOG ) , D.R. Horton ( NYSE:DHI )
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. PFE as his final trade.
In Article Trend: Somewhat-Bullish
March 13, 2024 (12:18) / "Benzinga" (by Meg Flippin)
Nanotechnology's Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX's Nanotechnology - AstraZeneca ( NASDAQ:AZN ) , FendX Technologies ( OTC:FDXTF )
From therapeutics to new drug delivery systems, nanotechnology can play an important role in fighting infectious diseases. A prime example is evident in the development of the COVID-19 vaccines. During the pandemic, Pfizer Inc. PFE, Moderna Inc. MRNA, Johnson & Johnson JNJ, AstraZeneca Plc.
In Article Trend: Neutral
March 13, 2024 (12:00) / "GlobeNewswire" (by Pyxis Oncology)
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
BOSTON, March 13, 2024 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. ( Nasdaq: "PYXS" ) , a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, ...
In Article Trend: Neutral
March 13, 2024 (11:20) / "Forbes" (by Robert Hart)
Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss Drugs
The stellar success of blockbuster drugs like Ozempic, Wegovy, Mounjaro and Zepbound has companies eager to break into the lucrative weight loss drug market - here are the hopeful rivals preparing to challenge Eli Lilly and Novo Nordisk for dominance in the obesity drug gold rush.
In Article Trend: Neutral
March 13, 2024 (10:12) / "Motley Fool" (by Adria Cimino and Keith Speights)
Moderna Stock: Bull vs. Bear
This stock delivered spectacular gains in the past.
In Article Trend: Neutral
March 13, 2024 (10:00) / "Business Insider" (by Reed Alexander)
How a boutique bank that rode last year's healthcare M&A streak into the big leagues plans to continue to compete with the JPMorgan's of the world
MTS Health Partners Is Seizing the Momentum of the Pfizer-Seagen Deal to Grow - Business Insider ...
In Article Trend: Somewhat-Bullish
March 13, 2024 (08:05) / "Business Standard" (by Capital Market)
Pfizer Ltd slips for fifth straight session
Pfizer Ltd is quoting at Rs 4217.85, down 2.23% on the day as on 13:19 IST on the NSE. The stock jumped 81.79% in last one year as compared to a 29.63% rally in NIFTY and a 60.88% spurt in the Nifty Pharma index. Pfizer Ltd dropped for a fifth straight session today.
In Article Trend: Somewhat-Bullish
March 12, 2024 (22:04) / "Business Insider" (by Brent D. Griffiths)
Robert Kennedy Jr. says he's seriously considering Jets QB Aaron Rodgers to be his running mate
RFK Jr. says he's considering Aaron Rodgers as his running mate - Business Insider ...
In Article Trend: Neutral
March 12, 2024 (16:57) / "Benzinga" (by Globe Newswire)
The Gross Law Firm Notifies BioNTech SE Investors of a Class Action Lawsuit and Upcoming Deadline - BNTX
NEW YORK, March 12, 2024 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE. Shareholders who purchased shares of BNTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
In Article Trend: Somewhat-Bearish
March 12, 2024 (15:10) / "Forbes" (by Ty Roush)
What To Know About Adcetris-Pfizer's Cancer Drug Extended Survival For Patients With Common Lymphoma
Pfizer's cancer drug Adcetris extended survival in patients with a common form of lymphoma in a late-stage trial, the company announced Tuesday, supporting Pfizer's efforts to expand into cancer treatments amid declining Covid vaccine sales.
In Article Trend: Somewhat-Bearish
March 12, 2024 (14:20) / "Benzinga" (by Globe Newswire)
Global Contraceptive Drugs Market Size is Projected to Reach USD 28.96 billion by 2030, Growing at a CAGR of 7.3%: Straits Research - Agile Therapeutics ( NASDAQ:AGRX ) , GSK ( NYSE:GSK )
New York, United States, March 12, 2024 ( GLOBE NEWSWIRE ) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases ( STDs ) , the transmission of sexually transmitted infections ( STIs ) , family planning, and birth control.
In Article Trend: Somewhat-Bullish
March 12, 2024 (12:55) / "Benzinga" (by Vandana Singh)
Pfizer-Acquired Seagen's Adcetris Combo Therapy Extends Overall Survival Versus Placebo In Patients With Most Common Type Of Lymphoma - Pfizer ( NYSE:PFE )
Tuesday, Pfizer Inc PFE announced that a Phase 3 study of the antibody-drug conjugate Adcetris ( brentuximab vedotin ) combined with lenalidomide and rituximab for relapsed/refractory diffuse large B-cell lymphoma ( DLBCL ) showed a statistically significant and clinically meaningful improvement ...
In Article Trend: Somewhat-Bullish
March 12, 2024 (12:00) / "GlobeNewswire" (by Veru Inc.)
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
MIAMI, March 12, 2024 ( GLOBE NEWSWIRE ) -- Veru Inc. ( NASDAQ: VERU ) , a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome ( ARDS ) , today ...
In Article Trend: Neutral
March 12, 2024 (09:39) / "Zacks Commentary" (by Zacks Equity Research)
J&J ( JNJ ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.
In Article Trend: Somewhat-Bullish
March 12, 2024 (02:52) / "South China Morning Post" (by Advertising partner)
QNET embraces Copilot for Microsoft 365 to supercharge productivity
The global wellness and lifestyle direct selling powerhouse is one of the early adopters of Copilot for Microsoft 365, recognising its immense potential for driving operational efficiency First-phase users are now testing the powerful tool after addressing AI concerns, exploring use cases to ...
In Article Trend: Bullish
March 12, 2024 (01:13) / "Forbes" (by Rodger Dean Duncan)
An MBA In 12 Weeks? These Guys Say It's Possible ( Maybe Preferable )
There's a lot of talk nowadays about what kind of education makes the most sense. For many jobs that once required a college degree, more emphasis is now placed on other factors like experience and demonstrated work ethic. People with a growth mindset are breaking a lot of barriers.
In Article Trend: Somewhat-Bullish
March 11, 2024 (18:51) / "Benzinga" (by Vandana Singh)
What's Going With Pfizer Stock On Monday? - Pfizer ( NYSE:PFE )
Pharmaceutical giant Pfizer Inc PFE is redirecting its strategic focus from COVID to cancer drugs to bounce back from a tumultuous year marked by a significant drop in its COVID-related business.
In Article Trend: Neutral
March 11, 2024 (18:42) / "Benzinga" (by Surbhi Jain)
Apple And 4 Other Stocks Redditors Consider Solid Value Picks Right Now - Alphabet ( NASDAQ:GOOGL ) , Starbucks ( NASDAQ:SBUX ) , Crocs ( NASDAQ:CROX ) , Pfizer ( NYSE:PFE )
Investors are on the lookout for undervalued stocks in the current market with Redditors at r/ValueInvesting sharing their insights. A user named D3Thijs expressed concerns about the high valuation of many stocks and sought suggestions for alternative investments.
In Article Trend: Bullish
March 11, 2024 (17:55) / "Benzinga" (by Globe Newswire)
BNTX DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX - BioNTech ( NASDAQ:BNTX )
NEW YORK, March 11, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE BNTX between March 30, 2022 and October 13, 2023, both dates inclusive ( the "Class Period" ) , of the important March 12, 2024 lead plaintiff ...
In Article Trend: Neutral
March 11, 2024 (16:24) / "Benzinga" (by Globe Newswire)
FINAL DEADLINE REMINDER FOR BNTX INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against BioNTech SE ( BNTX ) - BioNTech ( NASDAQ:BNTX )
RADNOR, Pa., March 11, 2024 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE ( ...
In Article Trend: Neutral
March 11, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Iron Deficiency Injectable Market Size Is Expected To Reach A Value Of $20.6 Billion By 2028 As Per The Business Research Company's Iron Deficiency Injectable Global Market Report 2024
LONDON, March 11, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Iron Deficiency Injectable Global Market Report 2024, the iron deficiency injectable market is experiencing rapid growth, poised to expand from $12.75 billion in 2023 to $14.06 billion in 2024, representing a ...
In Article Trend: Somewhat-Bullish
March 11, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Keloids Treatment Market Analysis 2024-2033: Expected Market Size, Projected Growth Rate And Major Drivers As Per The Business Research Company's Keloids Treatment Global Market Report 2024
LONDON, March 11, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Keloids Treatment Global Market Report 2024, the keloids treatment market has witnessed robust growth in recent years, with a notable increase from $3.91 billion in 2023 to $4.14 billion in 2024, showcasing a ...
In Article Trend: Somewhat-Bullish
March 11, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
Pfizer's Options Frenzy: What You Need to Know - Pfizer ( NYSE:PFE )
Whales with a lot of money to spend have taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer PFE we detected 17 trades. If we consider the specifics of each trade, it is accurate to state that 52% of the investors opened trades with bullish expectations and 47% ...
In Article Trend: Neutral
March 11, 2024 (14:43) / "PR Newswire"
Code and Theory, a Stagwell (STGW) Network Company, Named Ad Age Business Transformation Agency of the Year - PR Newswire
Code and Theory, a Stagwell ( STGW ) Network Company, Named Ad Age Business Transformation Agency of the Year PR ...
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:45) / "Motley Fool" (by Prosper Junior Bakiny)
2 Dirt Cheap Dividend Stocks to Buy and Hold
These companies aren't popular on the market right now, but income investors will like them.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:28) / "Motley Fool" (by Justin Pope)
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
There are some great companies at attractive prices in the lucrative pharmaceutical space.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:04) / "Benzinga" (by Globe Newswire)
Alation Unveils Next Major Release of the Data Intelligence Platform Empowering Organizations to Deliver on Their Most Critical Data Initiatives
REDWOOD CITY, Calif., March 11, 2024 ( GLOBE NEWSWIRE ) -- Alation, Inc., the data intelligence company, today announced the next major release of the Alation Data Intelligence Platform, including a next-generation user interface and business lineage capabilities built for data and analytics ...
In Article Trend: Bullish
March 11, 2024 (13:04) / "Benzinga" (by Globe Newswire)
Alation Launches Business Lineage to Help Analytics Teams Increase Trust in Data and Accelerate Time to Insights
REDWOOD CITY, Calif., March 11, 2024 ( GLOBE NEWSWIRE ) -- Alation, Inc., the data intelligence company, today announced business lineage to provide business users with broad and rich visibility into data's journey as it flows and transforms through systems.
In Article Trend: Bullish
March 11, 2024 (11:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
MAINZ, Germany, March 11, 2024 - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research ( "AACR" ) Annual Meeting 2024 in San Diego, California, from April 5-10, ...
In Article Trend: Neutral
March 11, 2024 (10:25) / "PR Newswire" (by The Gross Law Firm)
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 12, 2024 in BioNTech Lawsuit - BNTX
NEW YORK, March 11, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE. Shareholders who purchased shares of BNTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
In Article Trend: Somewhat-Bearish
March 11, 2024 (08:00) / "Benzinga" (by Globe Newswire)
BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - BioNTech ( NASDAQ:BNTX )
NEW YORK, March 11, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioNTech SE ( "BioNTech" or "the Company" ) BNTX and certain of its officers.
In Article Trend: Neutral
March 11, 2024 (06:15) / "GlobeNewswire" (by Basilea Pharmaceutica AG)
Continued strong Cresemba® ( isavuconazole ) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Allschwil, Switzerland, March ...
In Article Trend: Neutral
March 10, 2024 (23:10) / "Motley Fool" (by Alex Carchidi)
1 Bruised Dividend Stock to Buy While It's Cheap, and 1 to Avoid
Having a viable recovery plan is key.
In Article Trend: Neutral
March 10, 2024 (13:35) / "Motley Fool" (by Rachel Warren)
Have $2,000? 2 Magnificent Stocks Ready for a Bull Run
These stocks are trading down, but investors may be overlooking some important points.
In Article Trend: Neutral
March 10, 2024 (12:00) / "CNBC" (by Annika Kim Constantino)
Pfizer is betting big on cancer drugs to turn business around after Covid decline - here's what to know
The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.
In Article Trend: Neutral
March 10, 2024 (10:35) / "Motley Fool" (by Keith Speights)
3 Dividend Stocks to Buy Hand Over Fist in March
Income investors might want to load up on these great dividend stocks.
In Article Trend: Somewhat-Bullish
March 9, 2024 (14:00) / "Motley Fool" (by Motley Fool Staff)
The AI Race Gets Litigious
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
In Article Trend: Neutral
March 9, 2024 (06:59) / "Motley Fool" (by Prosper Junior Bakiny)
1 Beaten-Down Stock That's Still Not Worth Buying
For this biotech, a rebound seems far too unlikely.
In Article Trend: Neutral
March 9, 2024 (06:14) / "Zacks Commentary" (by Zacks Equity Research)
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates
Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.
In Article Trend: Neutral
March 9, 2024 (03:30) / "Business Insider" (by Erin Snodgrass)
OpenAI announces 'improvements' to its governance structure nearly 5 months after Sam Altman's ouster
By clicking "Sign Up", you accept our Terms of Service and Privacy Policy . You can opt-out at any time. Access your favorite topics in a personalized feed while you're on the go. download the app Sign up to get the inside scoop on today's biggest stories in markets, tech, and business - ...
In Article Trend: Neutral
March 9, 2024 (02:00) / "Benzinga" (by Globe Newswire)
BIONTECH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm - BioNTech ( NASDAQ:BNTX )
NEW YORK, March 08, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioNTech SE ( "BioNTech" or the "Company" ) BNTX in the United States District Court for the ...
In Article Trend: Neutral
March 9, 2024 (01:53) / "Fox Business News" (by Brie Stimson)
OpenAI reinstates Sam Altman to board of directors with 'full confidence' after investigation
OpenAI has reinstated CEO Sam Altman to its board of directors, the company said Friday. "We have unanimously concluded that Sam and [OpenAI founder and president] Greg [Brockman] are the right leaders for OpenAI," Bret Taylor, Chair of the OpenAI Board, said in a Friday blog post.
In Article Trend: Neutral
March 8, 2024 (22:48) / "PR Newswire"
Protein Expression Market size to grow by USD 2.45 billion from 2023 to 2027, North America accounts for 37% of ... - PR Newswire
Protein Expression Market size to grow by USD 2.45 billion from 2023 to 2027, North America accounts for 37% of ... PR ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (22:44) / "CNBC" (by Hayden Field)
Sam Altman rejoins OpenAI board of directors as investigation into his ouster comes to a close
Sam Altman rejoined OpenAI's board of directors and the company added three new board members, along with announcing the results of an internal investigation.
In Article Trend: Neutral
March 8, 2024 (21:38) / "Motley Fool" (by Selena Maranjian)
Seeking Blue Chip Stocks for Your Portfolio? Here Are a Magnificent Seven to Consider.
Blue chips can be extra-dependable stock holdings, often delivering regular dividend income, as well.
In Article Trend: Somewhat-Bullish
March 8, 2024 (20:02) / "PR Newswire" (by U.S. Food and Drug Administration)
FDA Roundup: March 8, 2024
SILVER SPRING, Md., March 8, 2024 /PRNewswire/ -- Today, the U.S.
In Article Trend: Bullish
March 8, 2024 (18:43) / "Benzinga" (by Vandana Singh)
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO - Regenxbio ( NASDAQ:RGNX )
RBC Capital Markets upgraded REGENXBIO Inc RGNX, a company focused on developing gene therapies. Recently, REGENXBIO reported additional interim safety and efficacy data in the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne muscular dystrophy ( Duchenne ) ages 4 to 11.
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:59) / "Money Morning" (by Chris Johnson)
This is Just the Beginning of Mind Medicine
My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, "Why The Psychedelic Boom Is All but Inevitable" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.
In Article Trend: Somewhat-Bullish
March 8, 2024 (14:59) / "Business Insider" (by Dan DeFrancesco)
Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7
Pharma companies are seeing stocks surge thanks to weight-loss drugs - Business Insider ...
In Article Trend: Neutral
March 8, 2024 (05:22) / "Benzinga" (by Benzinga Neuro)
Retail Traders Ditch Tesla, Apple, Google For Pharma Stocks Like Ozempic-Maker Novo Nordisk And Eli Lilly: JPMorgan - Alphabet ( NASDAQ:GOOG ) , Apple ( NASDAQ:AAPL )
Retail traders have been observed to be selling off their shares in the 'Magnificent Seven' tech stocks, with a noticeable shift towards pharmaceutical stocks, according to a recent report by JPMorgan.
In Article Trend: Neutral
March 7, 2024 (19:25) / "Benzinga" (by Vandana Singh)
FDA Approves Pfizer's Leukemia Drug For Kids As Old As One Year - Pfizer ( NYSE:PFE )
Wednesday, the FDA approved Pfizer Inc's PFE inotuzumab ozogamicin ( Besponsa ) for pediatric patients one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia ( ALL ) . Efficacy was evaluated in a multicenter, single-arm, open-label study ...
In Article Trend: Neutral
March 7, 2024 (18:45) / "Benzinga" (by Globe Newswire)
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE ( BNTX ) - BioNTech ( NASDAQ:BNTX )
LOS ANGELES, March 07, 2024 ( GLOBE NEWSWIRE ) -- Glancy Prongay & Murray LLP ( "GPM" ) reminds investors of the upcoming March 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioNTech SE ( "BioNTech" or the ...
In Article Trend: Neutral
March 7, 2024 (17:28) / "Forbes" (by Robert Hart)
Ozempic Maker's New Weight Loss Pill Beats Wegovy In Early Trial - What To Know About Novo Nordisk's Amycretin
Ozempic maker Novo Nordisk on Thursday teased a potential successor to its blockbuster weight loss drug Wegovy, the latest in a line of next-generation obesity treatments in development as consumers flock to the powerful drugs and competitors including Eli Lilly, Pfizer and an array of startups ...
In Article Trend: Neutral
March 7, 2024 (15:31) / "Business Insider" (by Yuheng Zhan)
Retail traders have been ditching the Magnificent 7 for pharma stocks like Eli Lilly, says JPMorgan
Retail Traders Are Dumping Magnificent 7 for Pharma, JPMorgan Says - Markets Insider ...
In Article Trend: Neutral
March 7, 2024 (14:35) / "GlobeNewswire" (by Sagaliam Acquisition Corp)
SAGALIAM ACQUISITION CORP. ANNOUNCES DELISTING OF COMMON SHARES FROM NASDAQ
New York, NY, March 07, 2024 ( GLOBE NEWSWIRE ) -- Sagaliam Acquisition Corp. ( NASDAQ: "SAGAU", "SAGA", SAGAR" ) ( the "Company" ) received a Nasdaq Hearing Withdrawal letter ( "Notice" ) from the Listing Qualifications staff of the Nasdaq Stock Market LLC ( "Nasdaq" ) on March 6, 2024.
In Article Trend: Neutral
March 7, 2024 (14:21) / "Motley Fool" (by Alex Carchidi)
1 Wall Street Analyst Thinks Pfizer Stock Is Going to $45. Is It a Buy Around $26?
Betting in favor of this giant's recovery could be smart in the long term.
In Article Trend: Neutral
March 7, 2024 (14:06) / "PR Newswire" (by Protalix BioTherapeutics)
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
Company to host conference call and webcast at 8:30 a.m. EDT
In Article Trend: Neutral
March 7, 2024 (12:59) / "Zacks Commentary" (by Zacks Equity Research)
Gilead ( GILD ) & MRK's HIV Oral Combo Shows Efficacy in Phase II
Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.
In Article Trend: Neutral
March 7, 2024 (11:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech Announces Planned Retirement of Sean Marett
Mainz, Germany, March 7, 2024 ( GLOBE NEWSWIRE ) - BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech.
In Article Trend: Somewhat-Bullish
March 7, 2024 (10:51) / "Benzinga" (by Globe Newswire)
Omics-Based Clinical Trials Market to Reach USD 54.42 Billion to 2031 | InsightAce Analytic
Jersey City, NJ, March 07, 2024 ( GLOBE NEWSWIRE ) -- InsightAce Analytic Pvt.
In Article Trend: Somewhat-Bullish
March 7, 2024 (08:14) / "Economic Times" (by ETCFO Research)
India Inc CFOs stress on collaboration and innovation in navigating challenges during current volatile times - ETCFO
AT ETCFO Leadership Summit, leading finance leaders say CFOs need to adapt to the new normal by embracing change, fostering innovation, and increasing organisational risk-taking capabilities.
In Article Trend: Somewhat-Bullish
March 7, 2024 (06:15) / "Barrons" (by Josh Nathan-Kazis)
Biden Will Tout Lower Drug Prices in State of the Union. Big Pharma Might Be Losing the Fight.
Big Pharma Is Running Out of Time to Block Medicare Drug Price Negotiations ...
In Article Trend: Neutral
March 7, 2024 (02:24) / "Economic Times" (by ETCFO Staff)
ETCFO Leadership Summit 2024: CFOs resetting the new world order - ETCFO
Currently, India Inc's finance honchos are facing several headwinds geopolitical tensions are high, there's a dilemma over private capex, consumption is stagnant and compliance requirements are increasing. The 5th edition of the ETCFO Leadership Summit will expound on how CFOs can reset the new ...
In Article Trend: Neutral
March 6, 2024 (23:40) / "Associated Press" (by ALEXANDRA OLSON)
A federal judge has ordered a US minority business agency to serve all races
NEW YORK ( AP ) - A federal judge in Texas has ordered a 55-year-old U.S. agency that caters to minority-owned businesses to serve people regardless of race, siding with white business owners who claimed the program discriminated against them.
In Article Trend: Neutral
March 6, 2024 (22:00) / "Benzinga" (by Vandana Singh)
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows - GSK ( NYSE:GSK ) , Pfizer ( NYSE:PFE )
ViiV Healthcare, majority owned by GSK Plc GSK, with Pfizer Inc PFE and Shionogi Limited as shareholders, revealed data from a planned interim analysis of the LATITUDE phase 3 trial.
In Article Trend: Neutral
March 6, 2024 (21:36) / "The Atlantic" (by Jacob Stern)
He Got 49 COVID Shots in One Month!
On June 3, 2021, a roughly 60-year-old man in the riverside city of Magdeburg, Germany, received his first COVID vaccine. He opted for Johnson & Johnson's shot, popular at that point because unlike Pfizer's and Moderna's vaccines, it was one-and-done. But that, evidently, was not what he had in ...
In Article Trend: Neutral
March 6, 2024 (21:15) / "Canada Newswire" (by Endo International plc)
ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS
DUBLIN, March 6, 2024 /CNW/ -- Endo International plc ( OTC: ENDPQ ) today reported financial results for the fourth-quarter ended December 31, 2023. Reported Diluted Net Loss per Share from Continuing Operations ( 1 ) Adjusted Income from Continuing Operations ( 2 ) ( 3 )
In Article Trend: Somewhat-Bullish
March 6, 2024 (21:15) / "PR Newswire" (by Endo International plc)
ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS
DUBLIN, March 6, 2024 /PRNewswire/ -- Endo International plc ( OTC: ENDPQ ) today reported financial results for the fourth-quarter ended December 31, 2023. Reported Diluted Net Loss per Share from Continuing Operations ( 1 ) Adjusted Income from Continuing Operations ( 2 ) ( 3 )
In Article Trend: Somewhat-Bullish
March 6, 2024 (18:24) / "Benzinga" (by Adam Eckert)
What's Going On With Pfizer Stock Wednesday? - Pfizer ( NYSE:PFE )
Pfizer Inc PFE shares are trading higher Wednesday, bouncing back after the stock hit its lowest levels in more than 10 years this week. Here's what you need to know.
In Article Trend: Somewhat-Bullish
March 6, 2024 (17:08) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: What to know about CDC's new Covid recommendations
The CDC announced two new major Covid recommendations last week. Meanwhile, venture firm General Catalyst said it was buying Summa Health.
In Article Trend: Neutral
March 6, 2024 (16:30) / "Benzinga" (by Globe Newswire)
Encephalitis Treatment Market Overview 2024-2028: Expected Market Size, Major Growth Factors And Lucrative Segments As Per The Business Research Company's Encephalitis Treatment Global Market Report 2024
LONDON, March 06, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's encephalitis treatment global market report 2024, the encephalitis treatment market has exhibited robust growth in recent years, with a notable increase in market size.
In Article Trend: Somewhat-Bullish
March 6, 2024 (15:05) / "Benzinga" (by Globe Newswire)
Global Pediatric Clinical Trials Market Size is Estimated to Reach USD 22.69 billion by 2030, Growing at a CAGR of 5.24 %: Straits Research
New York, United States, March 06, 2024 ( GLOBE NEWSWIRE ) -- For many pediatric indications, only pediatric clinical trials can approve novel medications. Pharmaceutical and biotechnology businesses have shifted from in-house clinical research to CRO contracts ( CRO ) .
In Article Trend: Somewhat-Bullish
March 6, 2024 (13:36) / "Forbes" (by John LaMattina)
Early Impact Of The Inflation Reduction Act On Drug Discovery
Despite the concerns of the biopharma industry, the Inflation Reduction Act ( IRA ) has been enacted and with it, Medicare is allowed to negotiate the prices of drugs.
In Article Trend: Neutral
March 6, 2024 (11:59) / "Zacks Commentary" (by Zacks Equity Research)
3 DWS Mutual Funds to Buy for Alluring Returns
Invest in DWS mutual funds such as DCUSX, DESUX and KTCAX to build a diversified investment portfolio.
In Article Trend: Somewhat-Bullish
March 6, 2024 (11:45) / "GlobeNewswire" (by BioNTech SE)
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
MAINZ, Germany, March 6, 2024 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the Company will host a conference call and webcast that day at ...
In Article Trend: Neutral
March 6, 2024 (11:11) / "CNN" (by Mira Cheng)
A man deliberately got 217 Covid shots. Here's what happened
One German man has redefined "man on a mission." A 62-year-old from Magdeburg deliberately got 217 Covid-19 vaccine shots in the span of 29 months, according to a new study, going against national vaccine recommendations. That's an average of one jab every four days.
In Article Trend: Neutral
March 6, 2024 (04:37) / "PR Newswire"
Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's ... - PR Newswire
Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's ... PR ...
In Article Trend: Somewhat-Bullish
March 6, 2024 (02:00) / "Benzinga" (by Globe Newswire)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm - BioVie ( NASDAQ:BIVI ) , Archer-Daniels Midland ( NYSE:ADM )
NEW YORK, March 05, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioNTech SE BNTX, Mobileye Global Inc. MBLY, BioVie Inc.
In Article Trend: Neutral
March 5, 2024 (20:37) / "Benzinga" (by Adam Eckert)
Josh Brown Just Bought This Stock Trading At 11-Year Lows, Paying A 6.5% Dividend: 'They Always Find A Way To Rebuild' - Pfizer ( NYSE:PFE )
Ritholtz Wealth Management's Josh Brown believes the best opportunity in the market right now is in a pharmaceutical stock that's trading at the same price it was at more than 10 years ago. What To Know: Tuesday on CNBC's "Fast Money Halftime Report," Brown made the case for buying Pfizer Inc PFE ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (17:58) / "Zacks Commentary" (by Zacks Equity Research)
Bayer ( BAYRY ) Acquires BridgeBio's Cardiovascular Drug
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.
In Article Trend: Neutral
March 5, 2024 (17:57) / "Benzinga" (by Vandana Singh)
Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says - GSK ( NYSE:GSK ) , Pfizer ( NYSE:PFE )
The World Health Organization ( WHO ) released its latest HIV Drug Resistance ( HIVDR ) Report, shedding light on the growing areas of drug resistance and providing crucial recommendations for countries to navigate potential challenges.
In Article Trend: Neutral
March 5, 2024 (16:50) / "Benzinga" (by Globe Newswire)
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioNTech SE ( BNTX ) Shareholders - BioNTech ( NASDAQ:BNTX )
NEW YORK, March 05, 2024 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ( "BioNTech" or the "Company" ) BNTX of a class action securities lawsuit.
In Article Trend: Neutral
March 5, 2024 (16:16) / "Motley Fool" (by Prosper Junior Bakiny)
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
Here's why I'm not worried.
In Article Trend: Neutral
March 5, 2024 (12:30) / "GlobeNewswire" (by LAVA Therapeutics N.V.)
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 ( formerly SGN-EGFRd2/LAVA-1223 )
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023 Milestone triggered by clinical progress in Phase 1 study, initiated in ...
In Article Trend: Neutral
March 4, 2024 (22:33) / "Benzinga" (by Globe Newswire)
BioNTech SE investors: Please contact the Portnoy Law Firm to recover your losses; March 12, 2024 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises BioNTech SE ( "BioNTech" or the "Company" ) BNTX investors that a lawsuit was filed on behalf of investors that purchased B.
In Article Trend: Neutral
March 4, 2024 (21:03) / "The Economist" (by The Economist)
The battle over the trillion-dollar weight-loss bonanza
W drugs called -1 agonists help users shed fat, and with it the negative health effects of obesity. This can have life-changing effects for the people who take them. It is also increasingly affecting the lives of corporate citizens.
In Article Trend: Neutral
March 4, 2024 (16:39) / "Benzinga" (by Vandana Singh)
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges - Gilead Sciences ( NASDAQ:GILD ) , GSK ( NYSE:GSK )
The Biden administration is working to preserve a crucial federal mandate compelling health insurers to cover preventive care services, including HIV-preventing medication and cancer screenings, without additional costs to patients. This mandate is integral to the 2010 Affordable Care Act ( ACA ) ...
In Article Trend: Neutral
March 4, 2024 (16:00) / "PR Newswire"
Sedgwick appoints Emily Fink as Chief Marketing Officer - PR Newswire
Sedgwick appoints Emily Fink as Chief Marketing Officer PR ...
In Article Trend: Bullish
March 4, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer Inc. ( PFE ) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:00) / "Benzinga" (by Globe Newswire)
Tome Biosciences Forms Science and Technology Advisory Committee
WATERTOWN, Mass., March 04, 2024 ( GLOBE NEWSWIRE ) -- Tome Biosciences, Inc., the programmable genomic integration ( PGI ) company, announces the formation of its Science and Technology Advisory Committee ( STAC ) comprised of four leaders in the delivery, development and manufacturing of ...
In Article Trend: Neutral
March 4, 2024 (12:10) / "Benzinga" (by Globe Newswire)
Osteoarthritis Drugs Market Expected to Hit USD 17.7 billion by 2031, Growing at a CAGR of 8.5%: Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global osteoarthritis drugs market is projected to rise at a CAGR of 8.5% from 2023 to 2031. As per the report published by TMR, a valuation of US$ 17.7 billion is anticipated for the ...
In Article Trend: Neutral
March 4, 2024 (11:45) / "PR Newswire" (by Mallinckrodt plc)
Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands
DUBLIN, March 4, 2024 /PRNewswire/ -- Mallinckrodt plc ( "Mallinckrodt" or the "Company" ) , a global specialty pharmaceutical company, today announced that Paul O'Neill has been appointed Executive Vice President, Quality & Operations, Specialty Brands, effective immediately.
In Article Trend: Somewhat-Bullish
March 4, 2024 (11:25) / "Motley Fool" (by Rich Smith)
1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $1000. Is It a Buy Around $782?
There are two big reasons why Eli Lilly stock is as much as 5x more expensive than Pfizer.
In Article Trend: Neutral
March 4, 2024 (11:21) / "Motley Fool" (by Keith Speights)
1 S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
The picture for this stock might look bleak, but appearances can be deceiving.
In Article Trend: Neutral
March 4, 2024 (10:21) / "Motley Fool" (by Sean Williams)
3 Magnificent Ultra-High-Yield Dividend Stocks That Are Screaming Buys in March
These high-octane income stocks, which sport a scorching-hot average yield of 8.84%, can fatten the wallets of patient investors.
In Article Trend: Somewhat-Bullish
March 4, 2024 (09:00) / "Benzinga" (by Globe Newswire)
BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - BioNTech ( NASDAQ:BNTX )
NEW YORK, March 04, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioNTech SE ( "BioNTech" or "the Company" ) BNTX and certain of its officers.
In Article Trend: Neutral
March 4, 2024 (06:09) / "The Financial Express" (by Vikram Chaudhary)
The Emerald Isle: Why Ireland is attracting so many Indian students
Ireland is an unlikely education destination for Indian students - who have traditionally chosen the 'big four'. According to the Ministry of External Affairs, 1,324,954 Indian students were studying abroad in 2022 - 61% of whom were in the US, the UK, Canada and Australia.
In Article Trend: Somewhat-Bullish
March 4, 2024 (06:00) / "Benzinga" (by Globe Newswire)
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
Saint-Herblain ( France ) , March 4, 2024 - Valneva SE VALNVLA, a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe.
In Article Trend: Somewhat-Bullish
March 4, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
Saint-Herblain ( France ) , March 4, 2024 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe.
In Article Trend: Somewhat-Bullish
March 4, 2024 (06:00) / "Business Insider" (by markets.businessinsider.com)
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
Saint-Herblain ( France ) , March 4, 2024 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced that its senior management will participate at upcoming investor conferences in the United States and Europe.
In Article Trend: Somewhat-Bullish
March 4, 2024 (02:33) / "The Financial Express" (by Health Desk)
Oncology innovation thrives in India, despite funding dip of 54.8 percent in India in 2023
In the fast-evolving landscape of the global oncology sector, Tracxn's analysis reveals a narrative of groundbreaking innovation and funding trends.
In Article Trend: Somewhat-Bullish
March 3, 2024 (18:17) / "Motley Fool" (by David Jagielski)
Where Will Moderna Stock Be in 5 Years?
Can Moderna be a good stock to buy if it can no longer count on billions in revenue from its COVID vaccine?
In Article Trend: Neutral
March 3, 2024 (17:45) / "Motley Fool" (by Alex Carchidi)
Is Ginkgo Bioworks Destined to Be in a "Magnificent Seven" of Healthcare Stocks?
It isn't ready for membership today, but it could have a path in the future.
In Article Trend: Somewhat-Bullish
March 3, 2024 (14:50) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE ... PR ...
In Article Trend: Neutral
March 3, 2024 (12:30) / "Motley Fool" (by James Brumley)
1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Investors are so worried about a one-off situation that they're looking right past the bigger bullish picture.
In Article Trend: Neutral
March 3, 2024 (07:00) / "CNN" (by Casey Tolan)
How the fortune of one of America's biggest pharmaceutical families has quietly funded conservative causes | Politics
How the fortune of one of America's biggest pharmaceutical families has quietly funded conservative causes CNN International ...
In Article Trend: Somewhat-Bullish
March 3, 2024 (07:00) / "CNN" (by Casey Tolan)
How the fortune of one of America's biggest pharmaceutical families has quietly funded conservative causes | Politics
How the family fortune behind a major American pharma company has quietly funded conservative causes ...
In Article Trend: Somewhat-Bullish
March 3, 2024 (03:02) / "Business Insider" (by NEWSFILE)
BNTX DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
BNTX DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action ...
In Article Trend: Neutral
March 2, 2024 (18:10) / "Motley Fool" (by Prosper Junior Bakiny)
3 Reasons to Buy Moderna Stock
The company can still deliver excellent returns.
In Article Trend: Neutral
March 2, 2024 (14:52) / "Forbes" (by Joshua Cohen)
A Behind-The-Counter Classification Of Drugs Could Accelerate Rx-To-OTC Switches In U.S.
The switching of two products from prescription-only ( Rx ) to over-the-counter last year hinted that there may be a wave of similar switches on the horizon, and ones in therapeutic categories previously off limits to OTC availability.
In Article Trend: Neutral
March 2, 2024 (05:30) / "Business Standard" (by Capital Market)
Volumes spurt at Aurobindo Pharma Ltd counter | Capital Market News
Volumes spurt at Aurobindo Pharma Ltd counter Business Standard ...
In Article Trend: Somewhat-Bullish
March 2, 2024 (02:00) / "Benzinga" (by Globe Newswire)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm - BioVie ( NASDAQ:BIVI ) , Archer-Daniels Midland ( NYSE:ADM )
NEW YORK, March 01, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioNTech SE BNTX, Mobileye Global Inc. MBLY, BioVie Inc.
In Article Trend: Neutral
March 2, 2024 (00:46) / "Benzinga" (by Globe Newswire)
Important March 12, 2024 Deadline Reminder for BioNTech SE Investors: Kessler Topaz Meltzer & Check, LLP Reminds BioNTech SE ( BNTX ) Investors of Securities Fraud Class Action Lawsuit - BioNTech ( NASDAQ:BNTX )
RADNOR, Pa., March 01, 2024 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE ( ...
In Article Trend: Neutral
March 1, 2024 (22:12) / "Motley Fool" (by Daniel Foelber)
Amazon Joined the Dow and Walmart Split Its Stock, but 9 Companies Still Make Up Over 50% of the Index
Stock splits don't matter in other indexes, but they do impact the Dow.
In Article Trend: Neutral
March 1, 2024 (15:34) / "Benzinga" (by Erica Kollmann)
Why Ginkgo Bioworks Stock Is Down After Earnings - Ginkgo Bioworks Holdings ( NYSE:DNA )
Ginkgo Bioworks Holdings, Inc. DNA shares are trading lower Friday after the company posted worse-than-expected fourth-quarter results and issued disappointing guidance. The company reported quarterly losses of 11 cents per share which missed the analyst consensus estimate of losses of 10 cents.
In Article Trend: Somewhat-Bullish
March 1, 2024 (12:31) / "Motley Fool" (by Prosper Junior Bakiny)
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks.
In Article Trend: Somewhat-Bullish
March 1, 2024 (03:36) / "PR Newswire"
Healthcare BPO Market size to grow by USD 12.90 billion from 2022 to 2027, Market growth Driven by the presence of ... - PR Newswire
Healthcare BPO Market size to grow by USD 12.90 billion from 2022 to 2027, Market growth Driven by the presence of ... PR ...
In Article Trend: Bullish
February 29, 2024 (22:34) / "MarketWatch" (by Lawrence G. McMillan)
The S&P 500 is overbought, but that doesn't mean it's time to sell
Signs of a market top are everywhere - and investors are ignoring them for now.
In Article Trend: Neutral
February 29, 2024 (21:05) / "PR Newswire" (by Biohaven Ltd.)
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
• Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: • Portfolio targeting large indications including obesity, epilepsy, bipolar disorder, depression, obsessive-compulsive disorder ( OCD ) , migraine, ...
In Article Trend: Neutral
February 29, 2024 (19:04) / "Benzinga" (by Vandana Singh)
Pfizer's Respiratory Syncytial Virus Vaccine Maintains Staying Power In Older Adults Through 2nd RSV season, Study Finds - Pfizer ( NYSE:PFE )
Thursday, Pfizer Inc PFE announced top-line Abrysvo vaccine efficacy and safety data for respiratory syncytial virus ( RSV ) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 trial RENOIR.
In Article Trend: Neutral
February 29, 2024 (16:30) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Down 0.2% Since Last Earnings Report: Can It Rebound?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
February 29, 2024 (16:30) / "Benzinga" (by Globe Newswire)
Retinal Vein Occlusion Market Overview 2024-2028: Projected Market Size, Leading Growth Factors, And Top Segments As Per The Business Research Company's Retinal Vein Occlusion Global Market Report 2024
LONDON, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Retinal Vein Occlusion Global Market Report 2024, the retinal vein occlusion market has witnessed rapid expansion, soaring from $13.79 billion in 2023 to $15.43 billion in 2024, boasting a remarkable compound ...
In Article Trend: Bullish
February 29, 2024 (16:30) / "Benzinga" (by Globe Newswire)
Urinary Tract Cancer Market To Grow At A CAGR Of More Than 19% With The Rising Prevalence Of Urinary Tract Infections As Per The Business Research Company's Urinary Tract Cancer Global Market Report 2024
LONDON, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's urinary tract cancer global market report 2024, the urinary tract cancer market has experienced remarkable growth in recent years, surging from $2.65 billion in 2023 to $3.21 billion in 2024, representing a ...
In Article Trend: Neutral
February 29, 2024 (15:49) / "PR Newswire" (by PA Consulting Group - US)
New clinical trials report from PA Consulting suggests biopharma companies are not keeping pace with changing public attitudes to sharing their medical data
New clinical trials report from PA Consulting suggests biopharma companies are not keeping pace with changing ... PR ...
In Article Trend: Bullish
February 29, 2024 (15:35) / "Benzinga" (by Globe Newswire)
Global Onychomycosis Treatment Market Size is Estimated to Reach USD 4.51 Billion by 2030, Growing at a CAGR of 5.61%: Straits Research
New York, United States, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- Onychomycosis is a fungal condition that affects the fingernails and toenails and can be painful, ugly, and persistent. Several types of onychomycosis include proximal subungual, white superficial, and distal subungual.
In Article Trend: Neutral
February 29, 2024 (13:50) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively ...
In Article Trend: Somewhat-Bullish
February 29, 2024 (13:00) / "CNBC" (by Annika Kim Constantino)
Pfizer RSV vaccine maintains protection in older adults over two seasons in trial
The results come ahead of a meeting of an advisory panel to the CDC, which will consider whether seniors should take RSV shots annually or every other year.
In Article Trend: Neutral
February 29, 2024 (12:45) / "Motley Fool" (by George Budwell)
Viking Therapeutics: A Teachable Moment About Investing for the Long Term
The biotherapeutics company's weight loss candidate scored a major win this week.
In Article Trend: Neutral
February 29, 2024 (07:07) / "Benzinga" (by Benzinga Neuro)
CDC Urges Second COVID-19 Vaccine Dose For Elderly Americans Amid Rising Hospitalizations
The Centers for Disease Control and Prevention ( CDC ) has recommended a second annual COVID-19 vaccine for individuals aged 65 and above. This decision comes in the wake of a significant increase in COVID-19 hospitalizations among older Americans.
In Article Trend: Neutral
February 29, 2024 (06:00) / "Benzinga" (by Globe Newswire)
U.S. CDC Advisory Committee ( ACIP ) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ®
Recommendation for use in travelers and laboratory workers follows U.S. Food and Drug Administration ( FDA ) approval in November 20231 IXCHIQ® is the first and only vaccine approved to address this unmet medical need in adults aged 18 years and older who are at increased risk of exposure to ...
In Article Trend: Neutral
February 29, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
U.S. CDC Advisory Committee ( ACIP ) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ®
U.S. CDC Advisory Committee ( ACIP ) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine ...
In Article Trend: Neutral
February 29, 2024 (03:00) / "Motley Fool" (by Motley Fool Transcribing)
DoubleVerify ( DV ) Q4 2023 Earnings Call Transcript
DV earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
February 28, 2024 (16:30) / "Benzinga" (by Globe Newswire)
Major Depressive Disorder Market Comprehensive Analysis: Market Size, Growth Factors And Top Trends As Per The Business Research Company's Major Depressive Disorder Global Market Report 2024
LONDON, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company, the major depressive disorder market has witnessed steady growth in recent years, driven by advancements in treatment options and increased awareness of mental health issues.
In Article Trend: Neutral
February 28, 2024 (15:25) / "Business Standard" (by Reuters)
Still facing strong headwinds, 2024 sales flat to lower, says Novavax | World News
Still facing strong headwinds, 2024 sales flat to lower, says Novavax Business Standard ...
In Article Trend: Neutral
February 28, 2024 (15:22) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX - BioNTech ( NASDAQ:BNTX )
NEW YORK, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE ( "BioNTech" or the "Company" ) BNTX. The class action, filed in the United States District Court for the Central District of California, and docketed under ...
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website